CARDINAL HEALTH INC, 10-K filed on 8/12/2025
Annual Report
v3.25.2
Cover Page - USD ($)
 12 Months Ended
Jun. 30, 2025
Jul. 31, 2025
Dec. 31, 2024
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Transition Report false    
Entity File Number 1-11373    
Entity Registrant Name Cardinal Health, Inc.    
Entity Incorporation, State or Country Code OH    
Entity Tax Identification Number 31-0958666    
Entity Address, Address Line One 7000 Cardinal Place    
Entity Address, City or Town Dublin,    
Entity Address, State or Province OH    
Entity Address, Postal Zip Code 43017    
City Area Code (614)    
Local Phone Number 757-5000    
Title of 12(b) Security Common shares (without par value)    
Trading Symbol CAH    
Security Exchange Name NYSE    
Entity Well-Known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 28,372,319,280
Entity Common Stock, Shares Outstanding   238,793,647  
Amendment Flag false    
Document Financial Statement Error Correction [Flag] false    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Entity Central Index Key 0000721371    
Current Fiscal Year End Date --06-30    
Documents Incorporated by Reference
Documents Incorporated by Reference:
Portions of the registrant’s Definitive Proxy Statement to be filed for its 2025 Annual Meeting of Shareholders are incorporated by reference into the sections of this Form 10-K addressing the requirements of Part III of Form 10-K.
    
Document Period End Date Jun. 30, 2025    
Auditor Location Grandview Heights, Ohio    
Auditor Name Ernst & Young LLP    
v3.25.2
Audit Information
 12 Months Ended
Jun. 30, 2025
Audit Information [Abstract]  
Auditor Name Ernst & Young LLP
Auditor Location Grandview Heights, Ohio
Auditor Firm ID 42
v3.25.2
Consolidated Statements of Earnings/(Loss) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]      
Revenue $ 222,578 $ 226,827 $ 204,979
Cost of products sold 214,410 219,413 198,105
Gross margin 8,168 7,414 6,874
Operating expenses:      
Distribution, selling, general, and administrative expenses 5,382 5,000 4,800
Restructuring and employee severance 88 175 95
Amortization and other acquisition-related costs 464 284 285
Acquisition-related cash and share-based compensation costs [Line Items] 126 0 0
Impairments and (gain)/loss on disposal of assets, net 18 634 1,246
Litigation (recoveries)/charges, net (185) 78 (304)
Operating earnings 2,275 1,243 752
Other (income)/expense, net (41) (9) 5
Interest expense, net 215 51 84
Earnings before income taxes 2,101 1,201 663
Income Tax Expense (Benefit) 532 348 332
Net earnings 1,569 853 331
Less: Net earnings attributable to noncontrolling interests (8) (1) (1)
Net earnings attributable to Cardinal Health, Inc. $ 1,561 $ 852 $ 330
Earnings per common share attributable to Cardinal Health, Inc.      
Basic (in dollars per share) $ 6.48 $ 3.48 $ 1.27
Diluted (in dollars per share) $ 6.45 $ 3.45 $ 1.26
Weighted-average number of common shares outstanding:      
Basic (in shares) 241 245 261
Diluted (in shares) 242 247 262
v3.25.2
Consolidated Statements of Comprehensive Income/(Loss) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Statement of Comprehensive Income [Abstract]      
Net earnings $ 1,569 $ 853 $ 331
Other comprehensive income/(loss):      
Foreign currency translation adjustments and other (3) (1) (35)
Net unrealized income/(loss) on derivative instruments, net of tax 15 (15) (2)
Total other comprehensive income/(loss), net of tax 12 (16) (37)
Total comprehensive income 1,581 837 294
Net Income (Loss) Attributable to Noncontrolling Interest 8 1 1
Total comprehensive income attributable to Cardinal Health, Inc. $ 1,573 $ 836 $ 293
v3.25.2
Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Current assets:        
Cash and equivalents $ 3,874 $ 5,133    
Trade receivables, net 13,242 12,084    
Inventories, net 16,831 14,957    
Prepaid expenses and other 2,414 2,663    
Assets held for sale 12 47    
Total current assets 36,373 34,884    
Property and equipment, net 2,858 2,529    
Goodwill and other intangibles, net 12,177 6,450    
Other assets 1,714 1,258    
Total assets 53,122 45,121    
Current liabilities:        
Accounts payable 34,713 31,759    
Current portion of long-term obligations and other short-term borrowings 550 434    
Other accrued liabilities 3,634 3,447    
Total current liabilities 38,897 35,640    
Long-term obligations, less current portion 7,977 4,658    
Deferred income taxes and other liabilities 8,882 8,035    
Preferred shares, without par value:        
Authorized—500 thousand shares, Issued—none 0 0    
Common shares, without par value:        
Authorized—755 million shares, Issued— 271 million shares 327 million shares at June 30, 2025 and 2024, respectively 2,956 2,917    
Retained earnings/(accumulated deficit) 783 (286)    
Common shares in treasury, at cost: 32 million shares and 83 million shares at June 30, 2025 and 2024, respectively (6,365) (5,677) $ (4,911) $ (3,128)
Accumulated other comprehensive loss (155) (167)    
Total Cardinal Health, Inc. shareholders' deficit (2,781) (3,213)    
Noncontrolling interests 147 1    
Total shareholders’ deficit (2,634) (3,212) $ (2,957) $ (882)
Total liabilities and shareholders’ deficit $ 53,122 $ 45,121    
v3.25.2
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Statement of Financial Position [Abstract]    
Preferred shares, authorized 500,000 500,000
Preferred shares, issued 0 0
Common shares, authorized 755,000,000 755,000,000
Common shares, issued 271,000,000 327,000,000
Common shares in treasury 32,000,000 83,000,000
Cash and equivalents $ 3,874 $ 5,133
Trade receivables, net 13,242 12,084
Inventories, net 16,831 14,957
Prepaid expenses and other 2,414 2,663
Assets held for sale 12 47
Property and equipment, net 2,858 2,529
Goodwill and other intangibles, net 12,177 6,450
Other assets 1,714 1,258
Accounts payable 34,713 31,759
Current portion of long-term obligations and other short-term borrowings 550 434
Other accrued liabilities 3,634 3,447
Long-term obligations, less current portion 7,977 4,658
Deferred income taxes and other liabilities 8,882 8,035
Authorized—500 thousand shares, Issued—none 0 0
Authorized—755 million shares, Issued— 271 million shares 327 million shares at June 30, 2025 and 2024, respectively 2,956 2,917
Retained earnings/(accumulated deficit) 783 (286)
Accumulated other comprehensive loss (155) (167)
Assets, Current 36,373 34,884
Total assets 53,122 45,121
Liabilities, Current 38,897 35,640
Noncontrolling interests 147 1
Treasury Stock, Value (6,365) (5,677)
Equity, Attributable to Parent (2,781) (3,213)
Equity, Including Portion Attributable to Noncontrolling Interest (2,634) (3,212)
Liabilities and Equity $ 53,122 $ 45,121
v3.25.2
Consolidated Statements of Shareholders' Equity/(Deficit) - USD ($)
shares in Thousands, $ in Millions
Total
GIA Common Stock [Member]
Retained Earnings/(Accumulated Deficit)
Treasury Shares
Accumulated Other Comprehensive Loss
Noncontrolling Interests
Balance at beginning of period (in shares) at Jun. 30, 2022   327,000        
Balance at beginning of period at Jun. 30, 2022 $ (882) $ 2,813 $ (456)   $ (114) $ 3
Common shares in treasury at Jun. 30, 2022       54,000    
Treasury, balance at beginning of period at Jun. 30, 2022 (3,128)          
Increase (Decrease) in Shareholders' Equity            
Net earnings 331         1
Net earnings 331          
Other comprehensive loss, net of tax (37)       (37)  
Purchase of noncontrolling interests 3         3
Employee stock plans activity, net of shares withheld for employee taxes (in shares)   0   3,000    
Employee stock plans activity, net of shares withheld for employee taxes 157 $ 33   $ 124    
Share repurchase program activity 2,000          
Share repurchase program activity   $ (100)        
Treasury shares acquired (in shares)       (24,600)    
Share repurchase program activity (2,007)     $ (1,907)    
Dividends declared (515)   (515)      
Other (1)   (1)    
Balance at end of period (in shares) at Jun. 30, 2023   327,000        
Common shares in treasury at Jun. 30, 2023       76,000    
Balance at end of period at Jun. 30, 2023 (2,957) $ 2,746 (642)   (151) 1
Treasury, balance at end of period at Jun. 30, 2023 (4,911)          
Increase (Decrease) in Shareholders' Equity            
Net Income (Loss) 330          
Net earnings 853         1
Other comprehensive loss, net of tax (16)       (16)  
Employee stock plans activity, net of shares withheld for employee taxes (in shares)   0   2,000    
Employee stock plans activity, net of shares withheld for employee taxes 164 $ 71   $ 93    
Share repurchase program activity 750          
Share repurchase program activity   $ 100        
Treasury shares acquired (in shares)       (9,000)    
Share repurchase program activity (759)     $ (859)    
Dividends declared (496)   (496)      
Other $ (1)       (1)
Balance at end of period (in shares) at Jun. 30, 2024 327,000 327,000        
Common shares in treasury at Jun. 30, 2024 83,000     83,000    
Balance at end of period at Jun. 30, 2024 $ (3,212) $ 2,917 (286)   (167) 1
Treasury, balance at end of period at Jun. 30, 2024 (5,677)          
Increase (Decrease) in Shareholders' Equity            
Net Income (Loss) 852          
Net earnings 1,569         8
Other comprehensive loss, net of tax 12       12  
Employee stock plans activity, net of shares withheld for employee taxes (in shares)   0   1,000    
Employee stock plans activity, net of shares withheld for employee taxes 108 $ 38   $ 70    
Share repurchase program activity 765        
Treasury shares acquired (in shares)       (6,400)    
Share repurchase program activity (757)     $ (757)    
Dividends declared (492)   (492)      
Other $ (1)     $ (1)   (1)
Balance at end of period (in shares) at Jun. 30, 2025 271,000 271,000        
Common shares in treasury at Jun. 30, 2025 32,000     32,000    
Balance at end of period at Jun. 30, 2025 $ (2,634) $ 2,956 $ 783   $ (155) 147
Treasury, balance at end of period at Jun. 30, 2025 (6,365)          
Increase (Decrease) in Shareholders' Equity            
Net Income (Loss) $ 1,561          
Treasury Stock, Shares, Retired 0 (56,000)   (56,000)    
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders $ (12)         (12)
Noncontrolling Interest, Increase from Business Combination $ 151         $ 151
v3.25.2
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Cash flows from operating activities:      
Net earnings $ 1,569 $ 853 $ 331
Adjustments to reconcile net earnings to net cash provided by operating activities:      
Depreciation and amortization 790 710 692
Impairments and loss on sale of other investments 3 2 7
Impairments and (gain)/loss on disposal of assets, net 18 634 1,246
Share-based compensation 244 121 96
Provision for/(benefit from) deferred income taxes 243 (104) (40)
Provision for bad debts 53 36 55
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:      
Increase in trade receivables (833) (996) (950)
(Increase)/decrease in inventories (1,816) 1,115 (412)
Increase in accounts payable 2,732 1,824 2,816
Other accrued liabilities and operating items, net (606) (433) (997)
Net cash provided by operating activities 2,397 3,762 2,844
Cash flows from investing activities:      
Additions to property and equipment (547) (511) (481)
Acquisition of subsidiaries, net of cash acquired (5,250) (1,190) (10)
Proceeds from net investment hedge terminations 2 34 29
Purchase of short-term time deposits 0 (550) 0
Proceeds from short-term investment in time deposit 200 350 0
Increase (decrease) in other investing items, net 2 18 8
Net cash used in investing activities (5,593) (1,849) (454)
Cash flows from financing activities:      
Proceeds from long-term obligations, net of issuance costs 3,669 1,139 0
Purchase of noncontrolling interests 12 0 3
Reduction of long-term obligations (445) (783) (579)
Net tax proceeds/(withholding) from share-based compensation (13) 46 56
Dividends on common shares (494) (499) (525)
Purchase of treasury shares (765) (750) (2,000)
Net cash provided by/(used in) financing activities 1,940 (847) (3,051)
Effect of exchange rates changes on cash and equivalents (3) (9) (8)
Net increase/(decrease) in cash and equivalents (1,259) 1,057 (669)
Cash and equivalents at beginning of period 5,133 4,076 4,745
Cash and equivalents at end of period 3,874 5,133 4,076
Supplemental Information:      
Cash payments for interest 315 214 203
Net cash payments for income taxes $ 444 $ 191 $ 156
v3.25.2
Business Combinations and Asset Acquisitions
 12 Months Ended
Jun. 30, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Business Combination
2. Acquisitions
Advanced Diabetes Supply Group ("ADS")
On April 1, 2025, we completed the acquisition of ADS, one of the country's leading diabetic medical supplies providers to patients in the home, for a purchase price of approximately $1.1 billion in cash, subject to certain adjustments. ADS serves approximately 500,000 patients annually by providing diabetes therapies from leading manufacturers. ADS is part of our at-Home Solutions operating segment and we report ADS results in Other.
We financed the acquisition of ADS with a combination of cash on hand and cash proceeds from new debt financing as described in Note 6.
Transaction and integration costs associated with the ADS acquisition were $31 million during fiscal 2025.
GI Alliance ("GIA")
On January 30, 2025, we completed the acquisition of a 73 percent ownership interest in GIA, a gastroenterology management services organization, for a purchase price of approximately $2.8 billion in cash, subject to certain adjustments. Beginning on the third anniversary of the closing, we have the ability to exercise a call right to purchase up to 100 percent of the remaining outstanding interests. GIA's management services organization platform includes over 900 physicians across 345 practice locations in 20 states and has the ability to further expand both geographically and in other key therapeutic areas.
We have accounted for the acquisition of the ownership interest in GIA as a business combination in accordance with ASC 805. We consolidate the results of GIA in our consolidated financial statements and report those consolidated results within our Pharma segment.
Additionally, on May 30, 2025, we, through GIA, completed the acquisition of Urology America, a urology management services organization, for a purchase price of $360 million in cash and GIA equity, subject to certain adjustments.
Transaction and integration costs associated with the GIA acquisitions were $75 million during fiscal 2025.
Integrated Oncology Network ("ION")
On December 2, 2024, we completed the acquisition of ION, a physician-led independent community oncology network, for a purchase price of $1.1 billion in cash, subject to certain adjustments. ION is a management services organization that supports more than 50 practice sites in 10 states representing more than 100 providers. ION supports a continuum of care across
its member sites including medical oncology, radiation oncology, urology diagnostic testing, and other ancillary services. As part of the transaction, ION practices were integrated into Navista, our managed services organization intended to enhance efficiency for providers and patients, enable additional capabilities, and increase practice profitability of independent community oncologists. We report ION results within our Pharma segment. The portion of ION net earnings attributable to noncontrolling interest holders is reported as a reduction to net earnings in the consolidated statements of earnings. The acquisition was funded with available cash on hand.
Transaction and integration costs associated with the ION acquisition were $30 million during fiscal 2025.
Specialty Networks
On March 18, 2024, we completed the acquisition of Specialty Networks for a purchase price of $1.2 billion in cash. Specialty Networks creates clinical and economic value for providers and partners across multiple specialty group purchasing organizations ("GPOs"): UroGPO, Gastrologix and GastroGPO, and United Rheumatology. Specialty Networks results are reflected within our Pharma segment.
Transaction and integration costs associated with the Specialty Network acquisition were $7 million and $16 million during fiscal 2025 and 2024, respectfully.
The acquisitions have positively impacted respective segment revenue and segment profit while increasing amortization and other acquisition-related costs and acquisition-related cash and share-based compensation costs during fiscal 2025.
Fair Value of Assets Acquired and Liabilities Assumed
The allocation of the purchase price for the acquisition of Urology America, ADS, GIA, and ION are not yet finalized and are subject to adjustment as we complete the valuation analysis of these acquisitions. The purchase prices are also subject to adjustment based on working capital requirements as set forth in the acquisition agreement.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date for Urology America, ADS, GIA, ION, and Specialty Networks:
(in millions)
Urology America
ADSGIAIONSpecialty
Networks
Identifiable intangible assets:
Customer intangibles (1)
$— $472 $— $226 $480 
Trade names (2)
33 28 200 73 15 
Developed technology and Other (3)— — — — 20 
Non-competition agreements (4)— — 23 — 5 
Total identifiable intangible assets acquired
33 500 223 299 520 
Identifiable net assets/(liabilities):
Cash and equivalents
4 14 53 8 23 
Trade receivables, net
24 97 191 59 17 
Inventories3 78 21 4 — 
Prepaid expenses and other3 8 14 5 2 
Property and equipment, net28 1 75 39 — 
Other assets
41 376 312 52 — 
Accounts payable(20)(104)(89)(10)— 
Current portion of long-term obligations and other short-term borrowings— — (1)(3)— 
Other accrued liabilities(11)(493)(173)(39)(13)
Long-term obligations, less current portion(6)— (15)(14)— 
Deferred income taxes and other liabilities(46)(12)(947)(90)(120)
Total identifiable net assets/(liabilities) acquired53 465 (336)310 429 
Noncontrolling interest— — — (151)— 
Goodwill
307 578 3,124 910 784 
Total net assets acquired
$360 $1,043 $2,788 $1,069 $1,213 
(1)    The weighted-average useful life of customer intangibles ranges from 10 years to 20 years.
(2)    The weighted-average useful life of trade names ranges from 2 years to 10 years.
(3)    The weighted-average useful life of developed technology and other is 8 years.
(4)    The weighted-average useful life of non-competition agreements is 4 years.
v3.25.2
Discontinued Operations and Disposal Groups
 12 Months Ended
Jun. 30, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]
3. Divestitures
Outcomes
On June 5, 2023, we signed a definitive agreement to contribute the Outcomes™ business to TDS, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a 16 percent equity interest in the combined entity. The transaction closed on July 10, 2023 and we recognized a pre-tax gain of $53 million during the three months ended September 30, 2023, which was included in impairments and (gain)/loss on disposal of assets, net in our consolidated statements of earnings. This gain includes our initial recognition of an equity method investment in the combined entity for $147 million, which was recorded in other assets in our consolidated balance sheets.
We determined that the divestiture of the Outcomes™ business does not meet the criteria to be classified as discontinued
operations. The Outcomes™ business operated and its results were reported within our Pharma segment before the divestiture.
v3.25.2
Restructuring and Employee Severance
 12 Months Ended
Jun. 30, 2025
Restructuring Charges [Abstract]  
Restructuring and Employee Severance
4. Restructuring and Employee Severance
The following table summarizes restructuring and employee severance costs:
(in millions)202520242023
Employee-related costs $61 $95 $39 
Facility exit and other costs 27 80 56 
Total restructuring and employee severance$88 $175 $95 
Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs, and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional project management and other service fees to support divestitures, costs associated with vacant facilities, and certain other divestiture-related costs.
Restructuring and employee severance costs in fiscal 2025, 2024, and 2023 include costs related to certain initiatives to rationalize our manufacturing operations and the implementation of certain enterprise-wide cost-savings measures. The increase in restructuring and employee severance in fiscal 2024 was primarily due to estimated severance costs related to these cost-savings measures and costs related to certain projects resulting from the reviews of our strategy, portfolio, capital-allocation framework, and operations. During fiscal 2023, restructuring and employee severance included costs related to the divestiture of the Cordis business.
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)Employee-
Related Costs		Facility Exit
and Other Costs		Total
Balance at June 30, 2023$44 $2 $46 
Additions74 13 87 
Payments and other adjustments(26)(10)(36)
Balance at June 30, 202492 5 97 
Additions40 — 40 
Payments and other adjustments(53)(5)(58)
Balance at June 30, 2025$79 $— $79 
v3.25.2
Goodwill and Other Intangible Assets
 12 Months Ended
Jun. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets
5. Goodwill and Other Intangible Assets
Goodwill
The following table summarizes the changes in the carrying amount of goodwill for the two reportable segments and the remaining operating segments, included in Other and in total:
(in millions)Pharmaceutical and Specialty Solutions
Global Medical Products and Distribution (1)
Other
(2) (3)
Total
Balance at June 30, 2023$2,762 $681 $1,170 $4,613 
Goodwill acquired, net of purchase price adjustments793 (3)— 790 
Foreign currency translation adjustments and other— (3)— (3)
Goodwill Impairment— (675)— (675)
Balance at June 30, 2024$3,555 $— $1,170 $4,725 
Goodwill acquired, net of purchase price adjustments4,389 — 578 4,967 
Foreign currency translation adjustments and other(1)— — (1)
Balance at June 30, 2025$7,943 $— $1,748 $9,691 
(1)    At June 30, 2025 and 2024, the GMPD segment accumulated goodwill impairment loss was $5.4 billion.
(2)    At June 30, 2025 and 2024, the Nuclear and Precision Health Solutions accumulated goodwill impairment loss was $829 million.
(3)    Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics.

The increase in the Pharma segment goodwill is primarily due to the GIA and ION acquisitions that occurred during fiscal 2025. The increase in the Other segment goodwill is due to the ADS acquisition that occurred during fiscal 2025. Goodwill recognized in connection with these acquisitions primarily represent the expected benefits from the expected growth from new customers, the assembled workforce of the acquired entities, and synergies of integrating these businesses. Substantially all of the goodwill recorded is expected to be nondeductible for income tax purposes.
During fiscal 2025, we did not identify any indicators of impairment within our reporting units.
We performed interim quantitative goodwill impairment testing for GMPD at September 30, 2023 and March 31, 2024, which resulted in pre-tax goodwill impairment charges of $585 million and $90 million, respectively. GMPD goodwill was fully impaired during the third quarter of fiscal 2024. During fiscal 2023, GMPD had cumulative pre-tax impairment charges of $1.2 billion. These goodwill impairment charges are recorded in impairments and
(gain)/loss on disposal of assets, net in our consolidated statements of earnings.
In connection with the divestiture of the Outcomes business, during fiscal 2023, we allocated and reclassified $24 million of goodwill from the Pharma operating segment to the Outcomes disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that was retained.
Other Intangible Assets
The following tables summarize other intangible assets by class at June 30:
2025
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible		Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents$13 $— $13 N/A
Total indefinite-life intangibles13 — 13 N/A
Definite-life intangibles:
Customer intangibles
3,876 2,639 1,237 11
Trademarks, trade names, and patents
1,340 459 881 8
Developed technology and other1,030 726 304 6
Non-Competition Agreements72 21 51 4
Total definite-life intangibles6,318 3,845 2,473 10
Total other intangible assets$6,331 $3,845 $2,486 N/A
2024
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible
Indefinite-life intangibles:
Trademarks and patents$12 $— $12 
Total indefinite-life intangibles12 — 12 
Definite-life intangibles:
Customer intangibles
3,628 2,431 1,197 
Trademarks, trade names, and patents
561 408 153 
Developed technology and other1,047 684 363 
Total definite-life intangibles5,236 3,523 1,713 
Total other intangible assets$5,248 $3,523 $1,725 
The increase in definite-life intangibles is primarily due to the ADS, GIA, and ION acquisitions. Total amortization of intangible assets was $303 million, $264 million, and $281 million for fiscal 2025, 2024, and 2023, respectively. The estimated annual amortization for intangible assets for fiscal 2026 through 2030 is as follows: $360 million, $364 million, $330 million, $307 million, and $284 million.
v3.25.2
Leases
 12 Months Ended
Jun. 30, 2025
Leases [Abstract]  
Leases
6. Leases
The following table summarizes the components of lease cost:
(in millions)202520242023
Operating lease cost$157 $120 $112 
Finance lease cost51 39 31 
Variable lease cost43 31 21 
Total lease cost$251 $190 $164 
Variable lease cost primarily includes payments for property taxes, maintenance, and insurance.
The following table summarizes supplemental balance sheet and other information related to leases at June 30:
(in millions)
20251
2024
Operating Leases
Operating lease right-of-use assets$758 $475 
Current portion of operating lease liabilities164 117 
Long-term operating lease liabilities654 400 
Total operating lease liabilities818 517 
Finance Leases
Finance lease right-of-use assets192 102 
Current portion of finance lease liabilities44 33 
Long-term finance lease liabilities157 75 
Total finance lease liabilities$201 $108 
Weighted-average remaining lease term (years)
Operating leases5.9 years5.5 years
Finance leases6.3 years4.1 years
Weighted-average discount rate
Operating leases3.9 %4.1 %
Finance leases4.6 %4.4 %
1 Increases in the right-of-use asset and liability balances are primarily due to acquisitions.
Operating leases are included in other assets, other accrued liabilities, and deferred income taxes and other liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, net, current portion of long-term obligations and other short-term borrowings, and long-term obligations, less current portion in our consolidated balance sheets.
The following table summarizes supplemental cash flow information related to leases:
(in millions)202520242023
Cash paid for lease liabilities:
Operating cash flows paid for operating leases$167 $124 $119 
Financing cash flows paid for finance leases53 36 31 
Non-cash right-of-use assets obtained in exchange for lease obligations:
New operating leases130 143 75 
New finance leases107 55 42 
Future lease payments under non-cancellable leases as of June 30, 2025 were as follows:
(in millions)Operating LeasesFinance LeasesTotal
2026$197 $52 $249 
2027174 45 219 
2028146 35 181 
2029111 25 136 
203097 19 116 
Thereafter199 57 256 
Total future lease payments924 233 1,157 
Less: imputed interest106 32 138 
Total lease liabilities$818 $201 $1,019 
v3.25.2
Long-Term Obligations and Other Short-Term Borrowings
 12 Months Ended
Jun. 30, 2025
Debt Disclosure [Abstract]  
Long-Term Obligations and Other Short-Term Borrowings
7. Long-Term Obligations and Other Short-Term Borrowings
The following table summarizes long-term obligations and other short-term borrowings at June 30:
(in millions) (1)20252024
3.5% Notes due 2024— 401 
3.75% Notes due 2025501 507 
4.7% Notes due 2026498 — 
3.41% Notes due 20271,206 1,191 
5.125% Notes due 2029645 644 
5.0% Notes due 2029745 — 
5.45% Notes due 2034501 491 
5.35% Notes due 2034989 — 
4.6% Notes due 2043323 308 
4.5% Notes due 2044338 330 
4.9% Notes due 2045438 423 
4.368% Notes due 2047566 563 
5.75% Notes due 2054641 — 
7.0% Debentures due 2026124 124 
Floating Rate Term Loan due 2028799 — 
Other Obligations213 110 
Total8,527 5,092 
Less: current portion of long-term obligations and other short-term borrowings550 434 
Long-term obligations, less current portion$7,977 $4,658 
(1)    Maturities are presented on a calendar year basis.
Maturities of existing long-term obligations and other short-term borrowings for fiscal 2026 through 2030 and thereafter are as follows: $553 million, $1.9 billion, $834 million, $670 million, $764 million, and $3.9 billion.
Long-Term Debt
All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. The 7.0% Debentures represent unsecured obligations of Allegiance Corporation (a wholly-owned subsidiary), which Cardinal Health, Inc. has guaranteed. None of these obligations are subject to a sinking fund and the Allegiance obligations are not redeemable prior to maturity. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $34.7 billion and $31.8 billion at June 30, 2025 and 2024, respectively.
During fiscal 2025, we issued additional debt, with the aggregate principal amount of $2.9 billion, to fund a portion of the consideration payable in connection with the GIA and ADS acquisitions and for general purposes. The notes issued are $500 million aggregate principal amount of 4.7% Notes that mature on November 15, 2026, $750 million aggregate principal amount of 5.0% Notes that mature on November 15, 2029, $1.0 billion aggregate principal amount of 5.35% Notes that mature on
November 15, 2034, and $650 million aggregate principal amount of 5.75% Notes that mature on November 15, 2054. The proceeds of the notes issued, net of discounts, premiums, and debt issuance costs, were $2.9 billion.
During fiscal 2025, we repaid the full principal of $400 million of the 3.5% Notes due 2024 at maturity with proceeds from the debt issuance in fiscal 2024, $200 million of which were invested in short-term time deposits and classified as prepaid expenses and other in our consolidated balance sheets at June 30, 2024. All short-term time deposits related to the debt issuance in fiscal 2024 have matured.
During fiscal 2024, we issued additional debt with the aggregate principal amount of $1.15 billion to fund the repayment of all of the aggregate principal amount outstanding of our 3.5% Notes due 2024 and 3.079% Notes due 2024, at their respective maturities, and for general corporate purposes. During fiscal 2024, we repaid the full principal of $750 million of the 3.079% Notes due 2024 at maturity. The notes issued are $650 million aggregate principal amount of 5.125% Notes that mature on February 15, 2029 and $500 million aggregate principal amount of 5.45% Notes that mature on February 15, 2034. The proceeds of the notes issued, net of discounts, premiums, and debt issuance costs were $1.14 billion.
If we undergo a change of control, as defined in the notes, and if the notes receive specified ratings below investment grade by each of Standard & Poor's Ratings Services, Moody’s Investors Services and Fitch Ratings, any holder of the notes, excluding the debentures, can require with respect to the notes owned by such holder, or we can offer, to repurchase the notes at 101% of the principal amount plus accrued and unpaid interest.
Other Financing Arrangements
In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $3.0 billion commercial paper program backed by a $2.0 billion revolving credit facility that expires in February 2028 and a $1.0 billion 364-Day revolving credit facility that expires in October 2025. We also have a $1.0 billion committed receivables sales facility.
On December 5, 2024, we entered into a term loan credit agreement that, among other things, provides commitments for a term loan facility in an aggregate amount of up to $1.0 billion. On April 1, 2025, we closed on our acquisition of ADS and borrowed $800 million under this term loan facility. The loan provided under this term loan credit agreement will mature in April 2028 and allows for prepayment, which may be accelerated pursuant to certain conditions specified in the credit agreement. Interest rates on borrowings will be based on prevailing interest rates, benchmarked based on Term SOFR and subject to our credit ratings.
In November 2024, we also obtained a commitment letter from a financial institution for a $2.9 billion unsecured bridge term loan facility that could have been used to complete the acquisition of GIA. We incurred fees related to the facility, which are included in interest expense, net. The unsecured bridge term loan facility was never entered into and we terminated the commitment letter on November 22, 2024.
In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025. In September 2023, Cardinal Health 23 Funding, LLC ("CH-23 Funding") was added as a seller under our committed receivables sales facility. Each of CHF and CH-23 Funding was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, each of CHF and CH-23 Funding is a separate legal entity from Cardinal Health, Inc. and from our respective subsidiary that sells receivables to CHF or CH-23 Funding, as applicable. Each of CHF and CH-23 Funding is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its respective creditors.
Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. As of June 30, 2025, we were in compliance with this financial covenant.
At June 30, 2025 and 2024, we had no amounts outstanding under the revolving credit facility; however, availability was reduced by outstanding letters of credit of $1 million at both June 30, 2025 and 2024.
During fiscal 2025, we had a daily maximum amount outstanding under our commercial paper and committed receivables programs of $633 million.
We had no amounts outstanding as of June 30, 2025 under the committed receivables sales facility program; however, availability was reduced by outstanding standby letters of credit of $31 million at both June 30, 2025 and 2024.
We had no amounts outstanding under the commercial paper program as of June 30, 2025 and 2024.
The $213 million and $110 million balance of other obligations at June 30, 2025 and 2024, respectively, consisted of finance leases and short-term borrowings.
v3.25.2
Fair Value Measurements
 12 Months Ended
Jun. 30, 2025
Fair Value Disclosures [Abstract]  
Fair Value Measurements
10. Fair Value Measurements
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at June 30:
2025
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,672 $— $— $1,672 
Other investments (1)108 — — 108 
Liabilities:
Forward contracts (2)— (48)— (48)
Share-based awards (3)— — (843)(843)
2024
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,442 $— $— $1,442 
Other investments (1)108 — — 108 
Liabilities:
Forward contracts (2)— (87)— (87)
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high-quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance
risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the consolidated balance sheets.
(3)The shared-based awards are comprised of liability-classified awards, as defined under ASC 718, resulting from the acquisition of GIA. The fair value of the GIA Units is determined using the discounted cash flow method. These are presented in deferred income taxes and other liabilities within the consolidated balance sheets. See Note 15 for additional information.
Fair Value Disclosures
10. Fair Value Measurements
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at June 30:
2025
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,672 $— $— $1,672 
Other investments (1)108 — — 108 
Liabilities:
Forward contracts (2)— (48)— (48)
Share-based awards (3)— — (843)(843)
2024
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,442 $— $— $1,442 
Other investments (1)108 — — 108 
Liabilities:
Forward contracts (2)— (87)— (87)
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high-quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance
risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the consolidated balance sheets.
(3)The shared-based awards are comprised of liability-classified awards, as defined under ASC 718, resulting from the acquisition of GIA. The fair value of the GIA Units is determined using the discounted cash flow method. These are presented in deferred income taxes and other liabilities within the consolidated balance sheets. See Note 15 for additional information.
v3.25.2
Financial Instruments
 12 Months Ended
Jun. 30, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments
11. Financial Instruments
We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.
Interest Rate Risk Management
We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.
Currency Exchange Risk Management
We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency revenue and expenses.
Commodity Price Risk Management
We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to
manage the price risk associated with certain forecasted purchases.
The following table summarizes the fair value of our assets and liabilities related to derivatives designated as hedging instruments and the respective line items in which they were recorded in the consolidated balance sheets at June 30:
(in millions)20252024
Assets:
Cross-currency swap (1)$— $12 
Foreign currency contracts (1)6 1 
Pay-floating interest rate swaps (1)14 3 
Total assets$20 $16 
Liabilities:
Cross-currency swap (2)$24 $1 
Foreign currency contracts (2)1 8 
Pay-floating interest rate swaps (2)43 94 
Total liabilities$68 $103 
(1)    Included in other assets in the consolidated balance sheets.
(2)    Included in deferred income taxes and other liabilities in the consolidated balance sheets.
Fair Value Hedges
We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the consolidated statements of earnings. During fiscal 2025, 2024, and 2023 there were no gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.
During fiscal 2024 and 2023, we entered into pay-floating interest rate swaps with total notional amounts of $500 million, and $300 million, respectively. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in the consolidated balance sheets.
The following tables summarize the outstanding interest rate swaps designated as fair value hedges at June 30, 2025 and 2024:
(in millions)Notional AmountMaturity Date
Pay-floating interest rate swaps$1,600 Jun 2027-Feb 2031
The following table summarizes the gain/(loss) recognized in earnings for interest rate swaps designated as fair value hedges:
(in millions)202520242023
Pay-floating interest rate swaps (1)$51 $2 $(50)
Fixed-rate debt (1)(51)(2)50 
(1)     Included in interest expense, net in the consolidated statements of earnings.

Cash Flow Hedges
We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency, and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.
Gains currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are $5 million.
We enter into foreign currency contracts to protect the value of anticipated foreign currency revenues and expenses. At June 30, 2025 and 2024, we held contracts to hedge probable, but not firmly committed, revenue and expenses. The principal currencies hedged are the Canadian dollar, Mexican peso, Chinese renminbi, Thai baht, and Philippine peso.
We enter into commodity contracts to manage the price risk associated with forecasted purchases of certain commodities used in our GMPD segment.
The following tables summarize the outstanding cash flow hedges at June 30:
 2025
(in millions)Notional AmountMaturity Date
Foreign currency contracts$381 Jul 2025-Jun 2026
 2024
(in millions)Notional AmountMaturity Date
Foreign currency contracts$401 Jul 2024-Jun 2025
The following table summarizes the pre-tax gain/(loss) included in OCI for derivative instruments designated as cash flow hedges:
(in millions)202520242023
Foreign currency contracts$11 $(7)$(2)
The following table summarizes the pre-tax gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges:
(in millions)202520242023
Foreign currency contracts (1)$3 $1 $9 
Foreign currency contracts (2)(6)4 2 
Foreign currency contracts (3)(1)— 1 
Forward interest rate swaps (4)2 2 2 
(1)    Included in revenue in the consolidated statements of earnings.
(2)    Included in cost of products sold in the consolidated statements of earnings.
(3)    Included in SG&A expenses in the consolidated statements of earnings.
(4)    Included in interest expense, net in the consolidated statements of earnings.
Net Investment Hedges
We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.
In February 2025, we entered into €100 million ($105 million) cross-currency swaps maturing in February 2027.
In February 2025, we terminated the €100 million ($107 million) cross-currency swaps entered into in March 2023 and received net settlement in cash of $2 million, recorded in proceeds from net investment hedge terminations in our consolidated statements of cash flows.
In June 2024, we terminated the ¥18 billion ($120 million) cross-currency swaps with a maturity date of June 2027 entered into in September 2023, and received net settlements in cash of $6 million, which was recorded in proceeds from net investment hedge terminations in our consolidated statements of cash flows.
In September 2023, we entered into ¥18 billion ($120 million) cross-currency swaps maturing in September 2025 and ¥18 billion ($120 million) cross-currency swaps maturing in June 2027.
In September 2023, we terminated the ¥38 billion ($300 million) cross-currency swaps entered into in January 2023 and received net settlement in cash of $28 million, recorded in proceeds from net investment hedge terminations in our consolidated statements of cash flows.
In January 2023, we entered into ¥19 billion ($150 million) cross-currency swaps maturing in September 2025 and ¥19 billion ($150 million) cross-currency swaps maturing in June 2027. In March 2023, we entered into €100 million ($107 million) cross-currency swaps maturing in March 2025, €100 million ($107 million) cross-currency swaps maturing in March 2026.
In January and March 2023, we terminated the ¥48 billion ($400 million) cross-currency swaps entered into in March 2022 and the €200 million ($233 million) cross-currency swap entered into in September 2018, respectively, and received net settlements in cash of $10 million and $19 million, respectively. These were recorded in proceeds from net investment hedge terminations in our consolidated statements of cash flows.
Cross-currency swaps designated as net investment hedges are marked-to-market using the current spot exchange rate as of the
end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.
Pre-tax gains and losses from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were a $33 million loss and a $26 million gain during fiscal 2025 and 2024, respectively. Gains recognized in interest expense, net in the consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $9 million and $14 million during fiscal 2025 and 2024, respectively.
Economic (Non-Designated) Hedges
We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions, and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net in the consolidated statements of earnings. The principal currencies managed through foreign currency contracts are the Canadian dollar, euro, Chinese renminbi, Mexican peso, and Brazilian real.
The following tables summarize the outstanding economic (non-designated) derivative instruments at June 30:
 2025
(in millions)Notional AmountMaturity Date
Foreign currency contracts$194 Jul 2025
 2024
(in millions)Notional AmountMaturity Date
Foreign currency contracts$178 Jul 2024
The following table summarizes the gain/(loss) recognized in earnings for economic (non-designated) derivative instruments:
(in millions)202520242023
Foreign currency contracts
$(6)$1 $(7)
Fair Value of Financial Instruments
The carrying amounts of cash and equivalents, trade receivables, net, accounts payable, and other accrued liabilities at June 30, 2025 and 2024 approximate fair value due to their short-term maturities.
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at June 30:
(in millions)20252024
Estimated fair value$8,388 $4,891 
Carrying amount8,527 5,092 
The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.
The following table is a summary of the fair value gain/(loss) of our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:
20252024
(in millions)Notional
Amount		Fair Value
Gain/(Loss)		Notional
Amount		Fair Value
Gain/(Loss)
Pay-floating interest rate swaps$1,600 $(29)$1,600 $(91)
Foreign currency contracts575 5 579 (7)
Cross-currency swap332 (24)334 11 
v3.25.2
Shareholders' Equity
 12 Months Ended
Jun. 30, 2025
Equity [Abstract]  
Shareholders' Equity
12. Shareholders' Deficit
At June 30, 2025 and 2024, authorized capital shares consisted of the following: 750 million Class A common shares, without par value; 5 million Class B common shares, without par value; and 500 thousand non-voting preferred shares, without par value. The Class A common shares and Class B common shares are collectively referred to below as “common shares.” Holders of common shares are entitled to share equally in any dividends declared by the Board of Directors and to participate equally in all distributions of assets upon liquidation. Generally, the holders of Class A common shares are entitled to one vote per share, and the holders of Class B common shares are entitled to one-fifth of one vote per share on proposals presented to shareholders for vote. Under certain circumstances, the holders of Class B common shares are entitled to vote as a separate class. Only Class A common shares were outstanding at June 30, 2025 and 2024.
We repurchased $3.5 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2025, 2024, and 2023, as described below. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.
During fiscal 2025, we repurchased 6.4 million common shares having an aggregate cost of $757 million. We repurchased 3.4 million and 3.0 million common shares under multiple accelerated share repurchase ("ASR") programs with average prices paid per common share of $110.10 and $125.87, respectively. These repurchases began on August 21, 2024 and concluded on March 11, 2025.
During fiscal 2025, we paid $15 million for excise taxes related to the completion of prior ASR programs and we retired 56 million of common stock shares without par value.
During fiscal 2024, we repurchased 9.0 million common shares having an aggregate cost of $759 million. We repurchased 0.9 million, 5.7 million, and 2.4 million common shares under multiple ASR programs with average prices paid per common share of $91.15, $88.22, and $103.67, respectively. These repurchases began on August 16, 2023 and concluded on December 13, 2023.
During fiscal 2023, we repurchased 24.6 million common shares having an aggregate cost of $2.0 billion. We repurchased 13.6 million, 3.2 million, 3.2 million, and 4.6 million common shares under multiple ASR programs with average prices paid per common share of $73.36, $77.50, $77.27, and $87.18, respectively. These repurchases began on September 14, 2022 and concluded on August 16, 2023.
Accumulated Other Comprehensive Loss
The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)Foreign
Currency
Translation
Adjustments and Other		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2023$(137)$(14)$(151)
Other comprehensive loss, before reclassifications(1)(7)(8)
Amounts reclassified to earnings— (8)(8)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $5 million
(1)(15)(16)
Balance at June 30, 2024(138)(29)(167)
Other comprehensive income/(loss), before reclassifications(3)13 10 
Amounts reclassified to earnings— 2 2 
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax benefit of $6 million
(3)15 12 
Balance at June 30, 2025$(141)$(14)$(155)
v3.25.2
Earnings Per Share Attributable to Cardinal Health, Inc.
 12 Months Ended
Jun. 30, 2025
Earnings Per Share [Abstract]  
Earnings Per Share Attributable to Cardinal Health, Inc.
13. Earnings Per Share Attributable to Cardinal Health, Inc.
The following table reconcile the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc. ("EPS"):
(in millions, except per share amounts)202520242023
Net earnings
$1,569 $853 $331 
Net earnings attributable to noncontrolling interest(8)(1)(1)
Net earnings attributable to Cardinal Health, Inc.
$1,561 $852 $330 
Weighted-average common shares–basic241 245 261 
Effect of dilutive securities:
Employee stock options, restricted share units, and performance share units
1 2 1 
Weighted-average common shares–diluted242 247 262 
Basic earnings per common share attributable to Cardinal Health, Inc.:
$6.48 $3.48 $1.27 
Diluted earnings per common share attributable to Cardinal Health, Inc.:
6.45 3.45 1.26 
The potentially dilutive employee stock options, restricted share units, and performance share units that were anti-dilutive were immaterial, 1 million, and 2 million for fiscal 2025, 2024, and 2023, respectively.
v3.25.2
Segment Information
 12 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Information
14. Segment Information
We operate under two reportable segments: Pharma and GMPD. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight®. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.
Our Pharma segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; repackages generic pharmaceuticals and over the counter healthcare products; and includes our managed services organization platforms for physician offices.
Our GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, which are sold in the United States, Canada, Europe, Asia, and other markets. This segment also distributes a broad range of medical, surgical, and laboratory products known as national brand products to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers in the United States and Canada.
The remaining three non-reportable operating segments included in Other are Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics. These operating segments respectively operate nuclear pharmacies and radiopharmaceutical manufacturing facilities, distribute medical products to patients' homes in the United States, and provide supply chain services and solutions to our customers.
Revenue
The following table presents revenue for the two reportable segments and disaggregated revenue within the remaining operating segments, included in Other, and Corporate:
(in millions)202520242023
Pharmaceutical and Specialty Solutions$204,644 $210,019 $188,814 
Global Medical Products and Distribution12,636 12,381 12,222 
Nuclear and Precision Health Solutions1,578 1,369 1,197 
at-Home Solutions3,480 2,869 2,584 
OptiFreight® Logistics
324 274 240 
Other5,382 4,512 4,021 
Total segment revenue222,662 226,912 205,057 
Corporate (1)(84)(85)(78)
Total revenue$222,578 $226,827 $204,979 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

The following table presents revenue by geographic area:
(in millions)202520242023
United States$220,993 $225,231 $203,440 
International1,669 1,681 1,617 
Total segment revenue222,662 226,912 205,057 
Corporate (1)(84)(85)(78)
Total revenue$222,578 $226,827 $204,979 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
The Company’s Chief Executive Officer, the chief operating decision maker ("CODM"), evaluates segment performance based on segment profit, among other measures. Segment profit is segment revenue less segment cost of products sold, less segment distribution, selling, general, and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate technology and shared functions expenses, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the operating segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
We do not allocate the following items to our segments:
•last-in first-out, or ("LIFO"), inventory charges/(credits);
•state opioid assessment related to prior fiscal years;
•shareholder cooperation agreement costs;
•restructuring and employee severance;
•amortization and other acquisition-related costs;
•acquisition-related cash and share-based compensation costs;
•impairments and (gain)/loss on disposal of assets, net;
•litigation (recoveries)/charges, net;
•other (income)/expense, net;
•interest expense, net;
•loss on early extinguishment of debt; or
•provision for/(benefit from) income taxes
In addition, certain investment spending, certain portions of enterprise-wide incentive compensation, and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $72 million, $59 million, and $35 million for fiscal 2025, 2024, and 2023, respectively.

The following tables present revenue, expenses, and segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
2025
(in millions)PharmaGMPDOther Total
Segment revenue
$204,644 $12,636 $5,382 $222,662 
Cost of products sold
199,999 10,470 4,023 214,492 
SG&A2,387 2,031 843 5,261 
Total segment expenses
202,386 12,501 4,866 219,753 
Segment profit$2,258 $135 $516 $2,909 
Corporate (1)(634)
Consolidated operating earnings
$2,275 
2024
(in millions)PharmaGMPDOther Total
Segment revenue
$210,019 $12,381 $4,512 $226,912 
Cost of products sold
205,864 10,264 3,367 219,495 
SG&A2,140 2,025 722 4,887 
Total segment expenses
208,004 12,289 4,089 224,382 
Segment profit$2,015 $92 $423 $2,530 
Corporate (1)(1,287)
Consolidated operating earnings
$1,243 
2023
(in millions)PharmaGMPDOther Total
Segment revenue$188,814 $12,222 $4,021 $205,057 
Cost of products sold184,814 10,377 2,990 198,181 
SG&A2,119 1,992 635 4,746 
Total segment expenses186,933 12,369 3,625 202,927 
Segment profit$1,881 $(147)$396 $2,130 
Corporate (1)(1,378)
Consolidated operating earnings$752 
(1)Corporate revenue and expenses consists of the elimination of inter-segment revenue and other revenue and expenses not allocated to the segments.

The following tables present depreciation and amortization and additions to property and equipment for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
(in millions)202520242023
Pharmaceutical and Specialty Solutions$185 $184 $194 
Global Medical Products and Distribution212 205 173 
Other88 79 71 
Corporate305 242 254 
Total depreciation and amortization$790 $710 $692 

(in millions)202520242023
Pharmaceutical and Specialty Solutions$118 $76 $56 
Global Medical Products and Distribution133 136 191 
Other88 81 52 
Corporate208 218 182 
Total additions to property and equipment$547 $511 $481 

The following table presents total assets for the two reportable segments and the remaining operating segments, included in Other, and Corporate at June 30:
(in millions)20252024
Pharmaceutical and Specialty Solutions$37,313 $29,149 
Global Medical Products and Distribution
6,889 7,047 
Other4,045 2,606 
Corporate4,875 6,319 
Total assets$53,122 $45,121 

The following table presents property and equipment, net by geographic area:
(in millions)20252024
United States$2,422 $2,106 
International436 423 
Property and equipment, net$2,858 $2,529 
v3.25.2
Share-Based Compensation
 12 Months Ended
Jun. 30, 2025
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation
15. Share-Based Compensation
We maintain Cardinal Health, Inc. stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors, and employees. Upon vesting these units convert to common shares without restrictions or future service requirements. At June 30, 2025, 15 million shares remain available for future grants under the Cardinal Health, Inc. 2021 Long-Term Incentive Plan ("2021 LTIP"). Under the 2021 LTIP's fungible share counting provisions, stock options are counted against the plan as one share for every share issued; awards other than stock options are counted against the plan as two and one-half shares for every share issued. This means that only 6 million shares could be issued under awards other than stock options while 15 million shares could be issued under stock options. Shares are issued out of treasury shares when stock options are exercised and when restricted share units and performance share units vest. Until the end of fiscal 2018, stock options were granted to our officers and certain employees. There were no stock options granted to employees during fiscal 2025, 2024, or 2023.
During fiscal 2024, we modified the equity incentive awards of four employees to amend provisions over involuntary termination. We recognized incremental share-based compensation expense of $9 million.
The following table provides total share-based compensation expense by type of award:
(in millions)202520242023
Restricted share unit expense$71 $77 $64 
Performance share unit expense50 44 32 
Total share-based compensation expense
$121 $121 $96 
The total tax benefit related to share-based compensation was $14 million, $16 million, and $12 million for fiscal 2025, 2024, and 2023, respectively. Share-based compensation expense is included in selling, general, and administrative expenses in the consolidated statements of earnings. Our consolidated statements of cash flows present our share-based compensation expense as a reconciling adjustment between net income and net cash provided by operating activities for all periods presented.
Restricted Share Units
Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)Restricted Share UnitsWeighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20232.2 $57.37 
Granted0.9 91.06 
Vested(1.2)60.47 
Canceled and forfeited(0.2)74.40 
Nonvested at June 30, 20241.7 70.98 
Granted0.7 108.72 
Vested(0.9)72.07 
Canceled and forfeited(0.1)94.67 
Nonvested at June 30, 20251.4 $86.30 
The following table provides additional data related to restricted share unit activity:
(in millions)202520242023
Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax$64 $71 $73 
Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years)222
Total fair value of shares vested during the year$60 $63 $58 
Performance Share Units
Performance share units generally vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the performance goals are achieved and the Company's TSR relative to the S&P 500 Health Care Index, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)Performance
Share Units		Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20231.2 $82.17 
Granted0.5 94.66 
Vested(0.4)62.26 
Canceled and forfeited— — 
Nonvested at June 30, 20241.3 97.03 
Granted0.5 113.88 
Vested(0.3)108.79 
Canceled and forfeited— — 
Nonvested at June 30, 20251.5 $99.45 

The following table provides additional data related to performance share unit activity:
(in millions)202520242023
Total compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized, pre-tax$47 $46 $38 
Weighted-average period over which performance share unit cost is expected to be recognized (in years)222
Total fair value of shares vested during the year$49 $20 $23 
Employee Retirement Savings Plans
Substantially all of our domestic non-union employees are eligible to be enrolled in our company-sponsored contributory retirement savings plans, which include features under Section 401(k) of the Internal Revenue Code of 1986 and provide for matching and discretionary contributions by us. The total expense for our employee retirement savings plans was $89 million, $65 million, and $66 million for fiscal 2025, 2024, and 2023, respectively.
v3.25.2
Schedule II - Valuations and Qualifying Accounts
 12 Months Ended
Jun. 30, 2025
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]
Cardinal Health, Inc. and Subsidiaries
Schedule II - Valuation and Qualifying Accounts
(in millions)Balance at
Beginning of Period		Charged to Costs
and Expenses (1)		Charged to
Other Accounts (2)		Deductions (3)Balance at
End of Period
Fiscal 2025
Accounts receivable$233 $88 $1 $(109)$213 
Finance notes receivable3 3 — (4)2 
Sales returns and allowances441 2,155 — (2,149)447 
$677 $2,246 $1 $(2,262)$662 
Fiscal 2024
Accounts receivable$240 $108 $— $(115)$233 
Finance notes receivable6 2 — (5)3 
Sales returns and allowances474 2,207 — (2,240)441 
$720 $2,317 $— $(2,360)$677 
Fiscal 2023
Accounts receivable$207 $165 $— $(132)$240 
Finance notes receivable8 — — (2)6 
Sales returns and allowances617 2,217 — (2,360)474 
$832 $2,382 $— $(2,494)$720 

(1)Fiscal 2025, 2024, and 2023 accounts receivable operating earnings impacts include $38 million, $74 million, and $109 million, respectively, for reserves related to service charges and customer disputes, excluded from provision for bad debts on the consolidated statements of cash flows and classified as a reduction in revenue in the consolidated statements of earnings.
(2)Recoveries of amounts provided for or written off were $1 million for fiscal 2025.
(3)Write-off of uncollectible accounts or actual sales returns.
The sum of the components may not equal the total due to rounding.
v3.25.2
Subsequent Events
 12 Months Ended
Jun. 30, 2025
Subsequent Events [Abstract]  
Subsequent Events
16. Subsequent Events
Solaris Health
On August 12, 2025, we announced that we, through GIA, have entered into a definitive agreement to acquire Solaris Health, a urology MSO, for a purchase price of approximately $1.9 billion in cash, subject to certain adjustments. In connection with the closing of this transaction, we will issue common units in GIA to certain physicians and management which are estimated to have a grant date fair value of approximately $500 million, a portion of which will be recognized as post-combination expense.
Solaris Health includes more than 750 providers across more than 250 practice locations in 14 states. Solaris Health will become part of The Specialty Alliance, our multi-specialty MSO platform, and their results will be reported within our Pharma segment. Following the closing of this transaction, we will own approximately 75% of The Specialty Alliance. This transaction is subject to the satisfaction of customary closing conditions, including receipt of required physician and regulatory approvals.
We intend to finance the announced transaction with a combination of cash on hand and cash proceeds from new debt financing.
v3.25.2
Insider Trading Arrangements
 3 Months Ended
Jun. 30, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.2
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Jun. 30, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Risk Management and Strategy
As a large healthcare distribution and services company, we are exposed to various cybersecurity threats and cybersecurity risk management is integral to our overall enterprise risk management strategy. We identify, assess, and manage risks related to cybersecurity through documented policies, standards, and procedures. Our approach to detection, mitigation, remediation, and prevention of cybersecurity risks utilizes a range of measures including, among other elements: benchmarking to generally accepted industry standards and frameworks, such as the National Institute of Standards and Technology cybersecurity framework; use of periodic tabletop exercises to promote awareness and improve internal processes; periodic penetration testing; a dedicated staff of cybersecurity professionals; and implementation of security measures and policies intended to identify as well as assist in containing and remediating cybersecurity risks. We maintain cybersecurity incident response, disaster recovery, and business continuity plans that govern activities such as preparation, detection coordination, remediation and recovery, and escalation to senior management and, where appropriate, relevant committees of the Board. These plans are routinely reviewed under the leadership of our Chief Information Security Officer ("CISO"). We also maintain mandatory employee cybersecurity and privacy compliance awareness training, which is supplemented by employee engagement campaigns.
We utilize third parties to assist with, and assess the effectiveness of, our cybersecurity posture, in addition to supporting incident response and mitigation where necessary. We identify and assess third party risks associated with suppliers and service providers across a range of areas, including cybersecurity, through a third-party risk management process that incorporates, among other features, the use of risk assessments and, where appropriate, contractual requirements around evaluations, security, technology, service levels, and other terms.
To date, we are not aware of cybersecurity incidents that have materially affected or are reasonably likely to materially affect Cardinal Health. However, the scope and impact of any future
incident cannot be predicted. For more information, please see Item 1A “Risk Factors” for the risk factor entitled “Our business and results of operations could be adversely affected if we experience a material cyber-attack or other systems breach.”
Cybersecurity Risk Board of Directors Oversight [Text Block]
Governance
Our CISO, in coordination with our Chief Information Officer (“CIO”) to whom the CISO reports, leads our approach to assessing and managing cybersecurity-related risks. Our CISO has over twenty-five years of experience in information technology (“IT”), with twenty years in IT risk management, compliance, and information security, as well as a background in leading technical infrastructure teams and roles supporting business operations.
As part of management’s oversight of our cybersecurity program, we maintain an IT risk governance process that includes multiple levels of escalation from our IT Risk Advisory Board, which meets on a monthly basis and whose membership includes the CISO and IT functional area leadership, to an executive-level committee to help address cybersecurity risks at an enterprise level.
The company’s Board oversees our overall risk management process. The Board has delegated to the Audit Committee primary responsibility for overseeing cybersecurity and other major technology-related risks and our actions to monitor and mitigate such risks. In coordination with the Audit Committee, the Risk Oversight Committee of the Board monitors Cardinal Health’s compliance with applicable legal and regulatory requirements, including with respect to data privacy and security. Our Audit Committee receives at least quarterly updates from the CISO and CIO and the Board receives at least annual cybersecurity updates. Among other items, these updates cover a range of matters relevant to our cybersecurity program, including: the threat environment and related business risks; the state, priorities of, and investments in our cybersecurity program; the availability of cyber insurance; review of certain cybersecurity incidents that have occurred within the company and the industry; and relevant cybersecurity operational metrics.
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Jun. 30, 2025
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
Our consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively. Certain prior year amounts have been reclassified to conform to the current year presentation.
Use of Estimates
Use of Estimates
Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments, and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates, judgments, and assumptions are used in the accounting and disclosure related to, among other items, allowance for doubtful accounts, inventory valuation and reserves, goodwill and other intangible asset impairment, vendor reserves, loss contingencies (including product liability and self-insurance accruals), and income taxes. Actual amounts may differ from these estimated amounts.
Cash Equivalents
Cash Equivalents
We consider liquid investments purchased with an initial effective maturity of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.
Receivables
Receivables and Allowance for Doubtful Accounts
Trade receivables are reported at their estimated collectible amounts and presented net of an allowance for doubtful accounts of $213 million and $233 million at June 30, 2025 and 2024, respectively. In addition to credit losses, the allowance also includes reserves related to customer disputes and late fees billed to customers, which are recognized within our consolidated statements of earnings as reductions of revenue. An account is considered past due on the first day after its due date. In
accordance with contract terms, we generally have the ability to charge customers service fees or higher prices if an account is considered past due. We regularly monitor past due accounts and establish appropriate reserves to cover potential losses, and consider historical experience, pricing discrepancies, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts.
We provide financing to various customers. Such financing arrangements range from 1 year to 5 years at interest rates that are generally subject to fluctuation. Interest income on these arrangements is recognized as it is earned. The financings may be collateralized, guaranteed by third parties or unsecured. Finance notes, net and related accrued interest were $32 million (current portion $7 million) and $43 million (current portion $14 million) at June 30, 2025 and 2024, respectively, and are included in other assets (current portion is included in prepaid expenses and other) in the consolidated balance sheets. Finance notes receivable allowance for doubtful accounts were $2 million and $3 million at June 30, 2025 and 2024, respectively. We estimate an allowance for these financing receivables based on historical collection rates and the creditworthiness of the customer. We write off any amounts deemed uncollectible against the established allowance for doubtful accounts.
Concentrations of Credit Risk
Concentrations of Credit Risk
We maintain cash depository accounts with major banks, and we invest in high quality, short-term liquid instruments, and in marketable securities. Our short-term liquid instruments mature within three months and we have not historically incurred any related losses.
Our trade receivables and finance notes and related accrued interest are exposed to a concentration of credit risk with certain large customers and with customers in the retail and healthcare sectors. Credit risk can be affected by changes in reimbursement and other economic pressures impacting the healthcare industry. With respect to customers in the retail and healthcare sectors, such credit risk is limited due to supporting collateral and the diversity of the customer base, including its wide geographic dispersion. We perform regular credit evaluations of our customers’ financial conditions and maintain reserves for losses through the established allowance for doubtful accounts. Historically, such losses have been within our expectations. Refer to the "Receivables and Allowance for Doubtful Accounts" section within this Note for additional information on the accounting treatment of reserves for allowance for doubtful accounts.
Major Customers
Major Customers
CVS Health Corporation ("CVS Health") is our only customer that individually accounted for at least 10 percent of revenue and/or gross trade receivables in fiscal 2025. In fiscal 2024, both CVS Health and OptumRx individually accounted for at least 10 percent of revenue and/or gross trade receivables. These customers were primarily serviced through our Pharmaceutical and Specialty Solutions ("Pharma") segment. Our pharmaceutical distribution contracts with OptumRx expired at the end of June 2024.
The following table summarizes historical percent of revenue and gross trade receivables from CVS Health and OptumRx:
Percent of RevenuePercent of Gross Trade Receivables at June 30
20252024202320252024
CVS Health30 %24 %25 %26 %22 %
OptumRx—17 %16 %—6 %
We have entered into agreements with group purchasing organizations (“GPOs”) which act as purchasing agents that negotiate vendor contracts on behalf of their members. Vizient, Inc. and Premier, Inc. are our two largest GPO member relationships in terms of revenue. Sales to members of these two GPOs collectively accounted for 27 percent, 16 percent, and 15 percent of revenue for fiscal 2025, 2024, and 2023, respectively. Our trade receivable balances are with individual members of the GPO, and therefore no significant concentration of credit risk exists with these types of arrangements
Inventories
Inventories
A portion of our inventories (52 percent and 50 percent at June 30, 2025 and 2024, respectively) are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These inventories are included within the core pharmaceutical distribution facilities of our Pharma segment (“distribution facilities”) and are primarily merchandise inventories. The LIFO method presumes that the most recent inventory purchases are the first items sold, so LIFO helps us better match current costs and revenue. We believe that the average cost method of inventory valuation provides a reasonable approximation of the current cost of replacing inventory within the distribution facilities. As such, the LIFO reserve is the difference between (a) inventory at the lower of LIFO cost or market and (b) inventory at replacement cost determined using the average cost method of inventory valuation.
At June 30, 2025 and 2024, inventories valued at LIFO cost were significantly in excess of the average cost value, respectively. We do not record inventories in excess of replacement cost. As such, we did not write-up the value of our inventory from average cost to LIFO cost at June 30, 2025 or 2024.
Our remaining inventory, including inventory in our Global Medical Products and Distribution ("GMPD") segment and certain inventory in our Pharma segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value. Net realizable value is defined as the estimated selling prices and estimated sales demand in the
ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.
We reserve for inventory obsolescence using estimates based on historical experience, historical and projected sales trends, specific categories of inventory, age and expiration dates of on-hand inventory, and manufacturer return policies. Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory which were $132 million and $149 million at June 30, 2025 and 2024, respectively.
Cash Discounts
Cash Discounts
Manufacturer cash discounts are recorded as a component of inventory cost and recognized as a reduction of cost of products sold as inventory is sold.
Property and Equipment
Property and Equipment
Property and equipment are carried at cost less accumulated depreciation. Property and equipment held for sale are recorded at the lower of cost less accumulated depreciation before the decision to dispose of the asset was made or fair value less cost to sell. When certain events or changes in operating conditions occur, an impairment assessment may be performed on the recoverability of the carrying amounts.
We capitalize project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application stage. Costs that are associated with the preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred.
Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which are depreciated over the terms of their respective leases. We generally use the following range of useful lives for our property and equipment categories: buildings and improvements—3 to 39 years; machinery and equipment—3 to 20 years; capitalized software held for internal use—3 to 7 years; and furniture and fixtures—3 to 7 years. We recorded depreciation and amortization of capitalized software of $488 million, $470 million, and $441 million for fiscal 2025, 2024, and 2023, respectively.
The following table presents the components of property and equipment, net at June 30:
(in millions)20252024
Land, building, and improvements
$2,178 $1,879 
Machinery and equipment2,685 2,367 
Capitalized software held for internal use1,940 1,744 
Furniture and fixtures136 128 
Construction in progress577 577 
Total property and equipment, at cost7,516 6,695 
Accumulated depreciation and amortization(4,658)(4,166)
Property and equipment, net$2,858 $2,529 

Repairs and maintenance expenditures are expensed as incurred. Interest on long-term projects is capitalized using a rate that approximates the weighted-average interest rate on long-term
obligations, which was 5 percent at June 30, 2025. The amount of capitalized interest was immaterial for all periods presented.
Business Combinations
The assets acquired and liabilities assumed in a business combination, including identifiable intangible assets, are recorded at their estimated fair values as of the acquisition date. The excess of the purchase price over the estimated fair value of the identifiable net assets acquired is recorded as goodwill. We base the fair values of identifiable intangible assets on detailed valuations that require management to make significant judgments, estimates, and assumptions. Critical estimates and assumptions include: expected future cash flows for customer relationships, trade names, developed technology, and other identifiable intangible assets; discount rates that reflect the risk factors associated with future cash flows; and estimates of useful lives. When an acquisition involves contingent consideration, we recognize a liability equal to the fair value of the contingent consideration obligation at the acquisition date. The estimate of fair value of a contingent consideration obligation requires subjective assumptions to be made regarding future business results, discount rates, discount periods, and probabilities assigned to various potential business result scenarios. See Note 2 for additional information regarding our acquisitions.
Business Combination
Business Combinations
The assets acquired and liabilities assumed in a business combination, including identifiable intangible assets, are recorded at their estimated fair values as of the acquisition date. The excess of the purchase price over the estimated fair value of the identifiable net assets acquired is recorded as goodwill. We base the fair values of identifiable intangible assets on detailed valuations that require management to make significant judgments, estimates, and assumptions. Critical estimates and assumptions include: expected future cash flows for customer relationships, trade names, developed technology, and other identifiable intangible assets; discount rates that reflect the risk factors associated with future cash flows; and estimates of useful lives. When an acquisition involves contingent consideration, we recognize a liability equal to the fair value of the contingent consideration obligation at the acquisition date. The estimate of fair value of a contingent consideration obligation requires subjective assumptions to be made regarding future business results, discount rates, discount periods, and probabilities assigned to various potential business result scenarios. See Note 2 for additional information regarding our acquisitions.
Goodwill and Other Intangible Assets
Goodwill and Other Intangible Assets
Purchased goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment annually or when indicators of impairment exist.
Purchased goodwill is tested for impairment at least annually. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. There is an option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the quantitative goodwill impairment test. We have elected to bypass the qualitative assessment for our annual goodwill impairment test in the current year. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount.
Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events, and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Following the acquisitions of Integrated Oncology Network ("ION"), GI Alliance ("GIA"), Advanced Diabetes Supply Group ("ADS"), and Urology America we have reassessed our reporting units for goodwill impairment testing.
As of June 30, 2025, our reporting units are: Pharma (excluding Navista & ION and GIA), Navista & ION, GIA, GMPD, Nuclear and Precision Health Solutions, OptiFreight® Logistics, at-Home Solutions, and ADS. We anticipate at-Home Solutions and ADS will be combined as a single reporting unit as the businesses are integrated in the future.
Fair value can be determined using market, income, or cost-based approaches. Our determination of estimated fair value of the reporting units is based on a combination of the income-based and market-based approaches. Under the income-based approach, we use a discounted cash flow model in which cash flows anticipated over several future periods, plus a terminal value at the end of that time horizon, are discounted to their present value using an appropriate risk-adjusted rate of return. We use our internal forecasts to estimate future cash flows, which we believe are consistent with those of a market participant, and include an estimate of long-term growth rates based on our most recent views of the long-term outlook for each reporting unit. Actual results may differ materially from those used in our forecasts. We use discount rates that are commensurate with the risks and uncertainty inherent in the respective reporting units and in our internally-developed forecasts. During fiscal 2025, discount rates used in our reporting unit valuations ranged from 9.5 to 11 percent. Under the market-based guideline public company method, we determine fair value by comparing our reporting units to similar businesses or guideline companies whose securities are actively traded in public markets. We also use the guideline transaction method to determine fair value based on pricing multiples derived from the sale of companies that are similar to our reporting units. To further confirm fair value, we compare the aggregate fair value of our reporting units to our total market capitalization. Estimating the fair value of reporting units requires the use of estimates and significant judgments that are based on a number of factors including forecasted operating results. The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment.
We performed annual impairment testing in fiscal 2025, 2024, and 2023 for our reporting units, which included Navista & ION in fiscal 2025. Due to the recent timing of their acquisitions, GIA and ADS were not included in our annual impairment testing in fiscal 2025 as no indicators of impairment were present.
During fiscal 2024 and 2023, we recognized goodwill impairment charges related to GMPD of $675 million and $1.2 billion, respectively, which were included in impairments and (gain)/loss on disposal of assets, net in our consolidated statements of earnings. GMPD had no goodwill balance remaining as of March 31, 2024.
We concluded that there were no impairments of goodwill for the remaining reporting units, excluding GMPD, in fiscal 2025, 2024, and 2023 as the estimated fair value of each reporting unit exceeded its carrying amount.
The impairment test for indefinite-lived intangibles other than goodwill involves first assessing qualitative factors to determine if it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount. If so, then a quantitative test is performed to compare the estimated fair value of the indefinite-lived intangible asset to the respective asset's carrying amount. Our qualitative evaluation requires the use of estimates and significant judgments and considers the weight of
evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying amount.
Intangible assets with finite lives, primarily customer relationships; trademarks, trade names, and patents; and developed technology, are amortized using a combination of straight-line and accelerated methods based on the expected cash flows from the assets over their estimated useful lives. We review intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment loss occurred requires a comparison of the carrying amount to the sum of the future forecasted undiscounted cash flows expected to be generated by the asset group. Actual results may differ materially from those used in our forecasts.
Assets Held for Sale, Policy [Policy Text Block]
Assets Held for Sale
We classify assets and liabilities (the “disposal group”) as held for sale when management commits to a plan to sell the disposal group in its present condition and at a price that is reasonable in relation to its current fair value. We also consider whether an active program to locate a buyer has been initiated and if it is probable that the sale will occur within one year without significant changes to the plan to sell. Upon classification of the disposal group as held for sale, we test the assets for impairment and cease related depreciation and amortization.
In June 2024, we signed an agreement to sell the West Campus Dublin, Ohio office space. At that time, we met the criteria for the related assets to be classified as held for sale. During fiscal 2025, the purchase agreement was terminated and the related assets were reclassified as assets held for use. We evaluated and recognized an impairment during fiscal 2025.
Investments
Investments
Investments in non-marketable equity securities are accounted for under the fair value, equity, or net asset value method of accounting and are included in other assets in the consolidated balance sheets. For equity securities without a readily determinable fair value, we use the fair value measurement alternative and measure the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which we can exercise significant influence but do not control, we use the equity method of accounting. Our share of the earnings and losses are recorded in other (income)/expense, net in the consolidated statements of earnings. We monitor our investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.
Vendor Reserves
Vendor Reserves
In the ordinary course of business, our vendors may dispute deductions taken against payments otherwise due to them or assert other disputes. These disputes are researched and resolved based upon the findings of the research performed. At any given time, there are outstanding items in various stages of research and resolution. In determining appropriate reserves for areas of exposure with our vendors, we assess historical experience and current outstanding claims. We have established various levels of reserves based on the type of claim and status of review. Though the claim types are relatively consistent, we periodically update our reserve estimates to reflect actual historical experience. The ultimate outcome of certain claims may be different than our original estimate and may require an adjustment. Adjustments to vendor reserves are included in cost of products sold. In addition, the reserve balance will fluctuate due to variations of outstanding claims from period-to-period, timing of settlements and specific
vendor issues. Vendor reserves were $96 million and $112 million at June 30, 2025 and 2024 respectively, excluding third-party returns. See "Third-Party Returns" section within this Note for a description of third-party returns.
Distribution Service Agreement and Other Vendor Fees
Distribution Services Agreement and Other Vendor Fees
Our Pharma segment recognizes fees received from distribution services agreements and other fees received from vendors related to the purchase or distribution of the vendors’ inventory when those fees have been earned and we are entitled to payment. Since the benefit provided to a vendor is related to the purchase and distribution of the vendor’s inventory, we recognize the fees as a reduction in the carrying value of the inventory that generated the fees, and as such, a reduction of cost of products sold in our consolidated statements of earnings when the inventory is sold.
Loss Contingencies
Loss Contingencies and Self-Insurance
Loss Contingencies
We accrue for contingencies related to disputes, litigation, and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
In connection with the opioid litigation as described further in Note 8, we recorded pre-tax charges of $5.6 billion during fiscal 2021, which were retained at Corporate. In February 2022, we and two other national distributors announced that each company had determined that a sufficient number of political subdivisions had agreed to participate in the previously disclosed National Opioid Settlement Agreement (the "NOSA") to settle the vast majority of the opioid lawsuits filed by states and local governmental entities. This NOSA became effective on April 2, 2022.
During fiscal 2024, we reached agreements to settle claims brought by classes of third-party payors and acute care hospitals, and the City of Baltimore.
We develop and periodically update reserve estimates for all litigation matters, including the Cordis OptEase and TrapEase inferior vena cava ("IVC") claims received to date and expected to be received in the future and related costs. To project future IVC claim costs, we use a methodology based largely on recent experience, including claim filing rates, blended average payout influenced by claim severity, historical sales data, implant and injury to report lag patterns, and estimated defense costs. At June 30, 2025, we have a total of $56 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our consolidated balance sheets, which includes the $49 million in the qualified settlement fund.
The amount of ultimate loss may differ materially from these estimates. We recognize these estimated loss contingencies, income from favorable resolution of litigation, and certain defense costs in litigation (recoveries)/charges, net in our consolidated statements of earnings. See Note 8 for additional information regarding loss contingencies and product liability lawsuits.
Self-Insurance
We self-insure for employee healthcare, general liability, certain product liability matters, auto liability, property, and workers'
compensation. Self-insurance accruals include an estimate for expected settlements or pending claims, defense costs, administrative fees, claim adjustment costs, and an estimate for claims incurred but not reported.
Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies and other liabilities is highly subjective and requires judgments about future events. We regularly review contingencies and our self-insurance accruals to determine whether our accruals and related disclosures are adequate. Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.
Guarantees, Indemnifications and Warranties Policies [Policy Text Block]
Guarantees
In the ordinary course of business, we agree to indemnify certain other parties under acquisition and disposition agreements, customer agreements, intellectual property licensing agreements, and other agreements. Such indemnification obligations vary in scope and, when defined, in duration. In many cases, a maximum obligation is not explicitly stated, and therefore the overall maximum amount of the liability under such indemnification obligations cannot be reasonably estimated. Where appropriate, such indemnification obligations are recorded as a liability. Historically, we have not, individually or in the aggregate, made payments under these indemnification obligations in any material amounts. In certain circumstances, we believe that existing insurance arrangements, subject to the general deduction and exclusion provisions, would cover portions of the liability that may arise from these indemnification obligations. In addition, we believe that the likelihood of a material liability being triggered under these indemnification obligations is not probable.
From time to time we enter into agreements that obligate us to make fixed payments upon the occurrence of certain events. Such obligations primarily relate to obligations arising under acquisition transactions, where we have agreed to make payments based upon the achievement of certain financial performance measures by the acquired business. Generally, the obligation is capped at an explicit amount. There were no material obligations at June 30, 2025.
Income Taxes
Income Taxes
We account for income taxes using the asset and liability method. Deferred tax assets and liabilities are measured using enacted tax rates in the respective jurisdictions in which we operate. We assess the realizability of deferred tax assets on a quarterly basis and provide a valuation allowance for deferred tax assets when it is more likely than not that at least a portion of the deferred tax assets will not be realized. The realizability of deferred tax assets depends on our ability to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction and also considers all available positive and negative evidence.
Deferred taxes for non-U.S. liabilities are not provided on the unremitted earnings of subsidiaries outside of the United States when it is expected that these earnings are indefinitely reinvested.
We operate in a complex multinational tax environment and are subject to tax treaty arrangements and transfer pricing guidelines for intercompany transactions that are subject to interpretation. Uncertainty in a tax position may arise as tax laws are subject to interpretation.
Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation processes. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.
See Note 9 for additional information regarding income taxes.
Other Accrued Liabilities, Policy [Policy Text Block]
Other Accrued Liabilities
Other accrued liabilities represent various current obligations, including certain accrued operating expenses, accrued rebates, and taxes payable.
Noncontrolling Interests and Redeemable Noncontrolling Interests
Noncontrolling Interests
Noncontrolling interests represent the portion of net earnings, comprehensive income, and net assets that is not attributable to Cardinal Health, Inc. Noncontrolling interests as of June 30, 2025 primarily represents third-party equity interests in ION. See Note 2, for additional information on the acquisition of ION.
Share-Based Compensation
Share-Based Compensation
Cardinal Health, Inc. Plan
Share-based compensation provided to employees is recognized in the consolidated statements of earnings based on the grant date fair value of the awards. The fair value of restricted share units
("RSUs") is determined by the grant date market price of our common shares. The fair value of performance share units ("PSUs"), which include a market-based condition, is determined using a Monte Carlo valuation model. The key assumptions for the Monte Carlo valuation model are as follows:
Award Year
Risk-Free Interest Rate (2)
Expected Volatility (3)
20233.12%32.41 %
2023 Modified (1)
5.13%26.58 %
20244.66%23.99 %
20253.89%24.54 %
(1)    There was a modification of prior year awards in fiscal 2024 that required a new Monte Carlo Simulation valuation model.
(2)    Based on the U.S. Treasury yields over a term comparable to the remaining performance period.
(3)    Based on historical volatility and implied volatility indications.
The compensation expense associated with nonvested PSUs is dependent on our periodic assessment of the probability of the performance goals being achieved. Based on the extent to which the performance goals are achieved and the Company's total shareholder return ("TSR") relative to the S&P 500 Health Care Index, vested shares may range from zero to 240 percent of the target award amount. Compensation expense is recognized regardless of the extent to which the market-based condition, the Company's relative TSR, is satisfied.
The compensation expense recognized for share-based awards is net of estimated forfeitures and is recognized ratably over the service period of the awards. All income tax effects of share-based awards are recognized in the consolidated statements of earnings as awards vest or are settled. We classify share-based compensation expense in distribution, selling, general, and administrative ("SG&A") expenses to correspond with the same line item as the majority of the cash compensation paid to employees. If awards are modified in connection with a restructuring activity, the incremental share-based compensation expense is classified in restructuring and employee severance. See Note 15 for additional information regarding share-based compensation.
GIA Share-Based Compensation
GIA, a majority-owned subsidiary of Cardinal Health, maintains standalone share-based compensation plans. In connection with the acquisition of physician practices, GIA issues common units in GIA (collectively the “GIA Units”) to certain physicians and management. The GIA Units contain forfeiture provisions ranging from 36 to 60 months. These forfeiture provisions provide that the unit holders forfeit all or a portion of the GIA Units should they leave GIA, except in certain limited situations, effectively requiring the unit holders to stay employed with the physician practice managed by GIA in order to retain all of the granted GIA Units during the forfeiture period.
These GIA Units are classified as liabilities under Accounting Standards Codification ("ASC") 718. The fair value of the vested GIA Units with no future service requirement are recorded as an assumed liability at the acquisition date. The fair value of GIA Units
with a future service requirement are recognized on a straight-line basis over the requisite service period.
The fair value of the GIA Units is remeasured at each reporting period using a discounted cash flow method. The compensation costs recognized each period reflects the change in the fair value of the liability for the portion of the awards for which the requisite service has been rendered.
See Note 15 for additional information regarding share-based compensation.
Dividends, Policy [Policy Text Block]
Dividends
We paid cash dividends per common share of $2.02, $2.00, and $1.98 in fiscal 2025, 2024, and 2023, respectively.
Revenue Recognition
Revenue Recognition
We recognize revenue in an amount that reflects the consideration to which we expect to be entitled in exchange for the transfer of goods or services to customers.
Revenue in our Pharma, GMPD, Nuclear and Precision Health Solutions, and at-Home Solutions operating segments is primarily related to the distribution of pharmaceutical and medical products, which include both manufactured and sourced products, and we recognize at a point in time when title transfers to customers and we have no further obligation to provide services related to such merchandise. OptiFreight® Logistics revenue is related to shipping, freight management, and logistics management services. Service revenues are recognized over the period that services are provided to the customer, reduced by contractual adjustments to third-party payors, discounts and implicit price concessions to customers. Revenues derived from services from all segments are immaterial for all periods presented.
We are generally the principal in a transaction, therefore our revenue is primarily recorded on a gross basis. When we are a principal in a transaction, we have determined that we control the ability to direct the use of the product or service prior to transfer to a customer, are primarily responsible for fulfilling the promise to provide the product or service to our customer, have discretion in establishing prices, and ultimately control the transfer of the product or services provided to the customer.
Sales Returns and Allowances
Sales Returns and Allowances
Revenue is recorded net of sales returns and allowances. Revenues are measured based on the amount of consideration that we expect to receive, reduced by estimates for return allowances, discounts, rebates, and other variable consideration. Sales returns are recorded based on estimates using historical data. Our customer return policies generally require that the product be physically returned, subject to restocking fees. We only allow customers to return products for credit in a condition suitable to be added back to inventory and resold at full value (“merchantable product”) or returned to vendors for credit. Product returns are generally consistent throughout the year and typically are not specific to any particular product or customer.
We accrue for estimated sales returns and allowances at the time of sale based upon historical customer return trends, margin rates, and processing costs. Our accrual for sales returns is reflected as
a reduction of revenue and cost of products sold for the sales price and cost, respectively. At June 30, 2025 and 2024, the accrual for estimated sales returns and allowances was $447 million and $441 million, respectively, which is reflected in trade receivables, net and inventories, net in the consolidated balance sheets. Sales returns and allowances were $2.2 billion, for fiscal 2025, 2024, and 2023, and the net impact on net earnings in the consolidated statements of earnings was immaterial in fiscal 2025, 2024, and 2023.
Third-Party Returns
We generally do not accept non-merchantable pharmaceutical product returns from our customers, so many of our customers return non-merchantable pharmaceutical products to the manufacturer through third parties. Since our customers generally do not have a direct relationship with manufacturers, our vendors pass the value of such returns to us (usually in the form of an accounts payable deduction). We, in turn, pass the value received to our customer. In certain instances, we pass the estimated value of the return to our customer prior to our receipt of the value from the vendor. Although we believe we have satisfactory protections, from time to time, we become subject to claims from customers or vendors that our administration of this overall process is deficient in some respect or our contractual terms with vendors are in conflict with our contractual terms with our customers. We maintain reserves for some of these situations based on their nature and our historical experience with their resolution.
Shipping and Handling
Shipping and Handling
Shipping and handling costs are primarily included in SG&A expenses in our consolidated statements of earnings and include all delivery expenses as well as all costs to prepare the product for shipment to the end customer. Shipping and handling costs were $909 million, $866 million, and $835 million, for fiscal 2025, 2024, and 2023, respectively.
Restructuring and Employee Severance
Restructuring and Employee Severance
Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance (including rationalizing headcount or other significant changes in personnel), and realigning operations (including realignment of the management structure in response to changing market conditions). Also included within restructuring and employee severance are employee severance costs that are not incurred in connection with a restructuring activity. See Note 4 for additional information regarding our restructuring activities.
Amortization and Other Acquisition-Related Costs
Amortization and Other Acquisition-Related Costs
We classify certain costs incurred in connection with acquisitions as amortization and other acquisition-related costs in our consolidated statements of earnings. These costs consist of amortization of acquisition-related intangible assets, amortization as a result of basis differences in equity method investments,
transaction costs, integration costs, and changes in the fair value of contingent consideration obligations. Transaction costs are incurred during the initial evaluation of a potential acquisition and primarily relate to costs to analyze, negotiate, and consummate the transaction as well as due diligence activities. Integration costs relate to activities required to combine the operations of an acquired enterprise into our operations and, in the case of the significant acquisitions with international operations, to stand-up the systems and processes needed to support an expanded geographic footprint. We record changes in the fair value of contingent consideration obligations relating to acquisitions as income or expense in amortization and other acquisition-related costs. See Note 5 for additional information regarding amortization of acquisition-related intangible assets.
Translation of Foreign Currencies
Translation of Foreign Currencies
Financial statements of our subsidiaries outside the United States are generally measured using the local currency as the functional currency. Adjustments to translate the assets and liabilities of these foreign subsidiaries into U.S. dollars are accumulated in shareholders’ equity through accumulated and other comprehensive loss ("AOCI") utilizing period-end exchange rates. Revenues and expenses of these foreign subsidiaries are translated using average exchange rates during the year.
The foreign currency translation gains/(losses) included in AOCI at June 30, 2025 and 2024 are presented in Note 12. Foreign currency transaction gains and losses for the period are included in the consolidated statements of earnings in the respective financial statement line item.
Interest Rate, Currency and Commodity Risk
Interest Rate, Currency, and Commodity Risk
All derivative instruments are recognized at fair value on the consolidated balance sheets and all changes in fair value are recognized in net earnings or shareholders’ equity through AOCI, net of tax.
For contracts that qualify for hedge accounting treatment, the hedge contracts must be effective at reducing the risk associated with the exposure being hedged and must be designated as a hedge at the inception of the contract. Hedge effectiveness is assessed periodically. Any contract not designated as a hedge, or so designated but ineffective, is adjusted to fair value and recognized immediately in net earnings. If a fair value or cash flow hedge ceases to qualify for hedge accounting treatment, the contract continues to be carried on the balance sheet at fair value until settled and future adjustments to the contract’s fair value are recognized immediately in net earnings. If a forecasted transaction is probable not to occur, amounts previously deferred in AOCI are recognized immediately in net earnings. Interest payments received from the cross-currency swap are excluded from the net investment hedge effectiveness assessment and are recorded in interest expense, net in the consolidated statements of earnings.
See Note 11 for additional information regarding our derivative instruments, including the accounting treatment for instruments designated as fair value, cash flow, net investment, and economic hedges.
Fair Value Measurements
Fair Value Measurements
Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are:
Level 1 -    Observable prices in active markets for identical assets and liabilities.
Level 2 -    Observable inputs other than quoted prices in active markets for identical assets and liabilities.
Level 3 -    Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
See Note 10 for additional information regarding fair value measurements.
Lessee, Leases
Leases
Our leases are primarily for corporate and physician offices, distribution facilities, vehicles, and equipment. We determine if an arrangement is a lease at its inception by evaluating whether the arrangement conveys the right to use an identified asset and whether we obtain substantially all of the economic benefits from and have the ability to direct the use of the asset. Our lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.
Operating lease right-of-use assets and corresponding operating lease liabilities are recognized in our consolidated balance sheets at lease commencement date based on the present value of lease payments over the lease term. Operating lease expense for operating lease assets is recognized on a straight-line basis over the lease term. As most of our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. We use the implicit rate if it is readily determinable.
Our lease agreements contain lease components and non-lease components. For all asset classes, we have elected to account for both of these components as a single lease component. We also, from time to time, sublease portions of our real estate property, resulting in sublease income. Sublease income and the related assets and cash flows are not material to the consolidated financial statements at or for the fiscal years ended June 30, 2025, 2024, and 2023.
We apply a practical expedient for short-term leases whereby we do not recognize a lease liability and right-of-use asset for leases with a term of less than 12 months. Short-term lease expense recognized in fiscal 2025, 2024, and 2023 was immaterial.
Our leases have remaining lease terms from less than 1 year up to approximately 17 years. Our lease terms may include options to extend or terminate the lease when it is reasonably certain and there is a significant economic incentive to exercise that option.
See Note 6 for additional information regarding leases.
Recent Financial Accounting Standards
Recently Adopted Financial Accounting Standards.
Segment Reporting
In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances reportable segment disclosure requirements, primarily through disclosures of significant segment expenses. The Company adopted the new guidance in our fiscal 2025 Form 10-K. The new standard did not have an impact on the company's consolidated financial statements but required additional disclosures. See Note 14 for additional information.
Recently Issued Financial Accounting Standards and Disclosure Rules Not Yet Adopted
We assess the adoption impacts of recently issued accounting standards by the FASB on our consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2024 Form 10-K.
Income Tax Disclosure
In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for us in our fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Disaggregation of Income Statement Expenses
In November 2024, the FASB issued ASU 2024-03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40), which requires
disaggregated disclosures of certain categories of expenses which are included in any relevant income statement expense caption on an annual and interim basis. Additionally, the guidance requires the disclosure of total selling expenses and, in annual reporting periods, an entity's definition of selling expenses. This guidance will be effective for us in our fiscal 2028 Form 10-K and should be applied on a prospective basis, with retrospective application permitted. We are currently evaluating the impact of adoption of this guidance on our disclosures.
Consolidation, Variable Interest Entity, Policy
Variable Interest Entities
We evaluate our ownership, contractual, and other interests in entities to determine if they are a variable interest entity (“VIE”), if we have a variable interest in those entities, and the nature and extent of those interests. These evaluations may involve management judgment and the use of estimates and assumptions based on available historical information, among other factors. Based on our evaluations, if we determine we are the primary beneficiary of such VIEs, we consolidate such entities into our financial statements.
Consolidated Variable Interest Entities
We consolidate a VIE when we have the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits of the VIE and, as a result, are considered the primary beneficiary of the VIE.
In relation to the acquisition of GIA, we concluded that GIA is the primary beneficiary and it consolidates the VIEs. The GIA VIEs do not have a material impact on our consolidated statements of earnings or consolidated statements of cash flows. Total assets and liabilities included in the consolidated balance sheets for the GIA VIEs were $601 million and $187 million, respectively, as of June 30, 2025.
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Jun. 30, 2025
Accounting Policies [Abstract]  
Schedule of Revenue and Gross Trade Receivables Percentage by Major Customers
The following table summarizes historical percent of revenue and gross trade receivables from CVS Health and OptumRx:
Percent of RevenuePercent of Gross Trade Receivables at June 30
20252024202320252024
CVS Health30 %24 %25 %26 %22 %
OptumRx—17 %16 %—6 %
Components of Property and Equipment
Property and Equipment
Property and equipment are carried at cost less accumulated depreciation. Property and equipment held for sale are recorded at the lower of cost less accumulated depreciation before the decision to dispose of the asset was made or fair value less cost to sell. When certain events or changes in operating conditions occur, an impairment assessment may be performed on the recoverability of the carrying amounts.
We capitalize project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application stage. Costs that are associated with the preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred.
Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including finance lease assets which are depreciated over the terms of their respective leases. We generally use the following range of useful lives for our property and equipment categories: buildings and improvements—3 to 39 years; machinery and equipment—3 to 20 years; capitalized software held for internal use—3 to 7 years; and furniture and fixtures—3 to 7 years. We recorded depreciation and amortization of capitalized software of $488 million, $470 million, and $441 million for fiscal 2025, 2024, and 2023, respectively.
The following table presents the components of property and equipment, net at June 30:
(in millions)20252024
Land, building, and improvements
$2,178 $1,879 
Machinery and equipment2,685 2,367 
Capitalized software held for internal use1,940 1,744 
Furniture and fixtures136 128 
Construction in progress577 577 
Total property and equipment, at cost7,516 6,695 
Accumulated depreciation and amortization(4,658)(4,166)
Property and equipment, net$2,858 $2,529 

Repairs and maintenance expenditures are expensed as incurred. Interest on long-term projects is capitalized using a rate that approximates the weighted-average interest rate on long-term
obligations, which was 5 percent at June 30, 2025. The amount of capitalized interest was immaterial for all periods presented.
Schedule Of Share-Based Payment Valuation Assumptions The key assumptions for the Monte Carlo valuation model are as follows:
Award Year
Risk-Free Interest Rate (2)
Expected Volatility (3)
20233.12%32.41 %
2023 Modified (1)
5.13%26.58 %
20244.66%23.99 %
20253.89%24.54 %
(1)    There was a modification of prior year awards in fiscal 2024 that required a new Monte Carlo Simulation valuation model.
(2)    Based on the U.S. Treasury yields over a term comparable to the remaining performance period.
(3)    Based on historical volatility and implied volatility indications.
v3.25.2
Business Combinations and Asset Acquisitions (Tables)
 12 Months Ended
Jun. 30, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Business Combination, Recognized Asset Acquired and Liability Assumed
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date for Urology America, ADS, GIA, ION, and Specialty Networks:
(in millions)
Urology America
ADSGIAIONSpecialty
Networks
Identifiable intangible assets:
Customer intangibles (1)
$— $472 $— $226 $480 
Trade names (2)
33 28 200 73 15 
Developed technology and Other (3)— — — — 20 
Non-competition agreements (4)— — 23 — 5 
Total identifiable intangible assets acquired
33 500 223 299 520 
Identifiable net assets/(liabilities):
Cash and equivalents
4 14 53 8 23 
Trade receivables, net
24 97 191 59 17 
Inventories3 78 21 4 — 
Prepaid expenses and other3 8 14 5 2 
Property and equipment, net28 1 75 39 — 
Other assets
41 376 312 52 — 
Accounts payable(20)(104)(89)(10)— 
Current portion of long-term obligations and other short-term borrowings— — (1)(3)— 
Other accrued liabilities(11)(493)(173)(39)(13)
Long-term obligations, less current portion(6)— (15)(14)— 
Deferred income taxes and other liabilities(46)(12)(947)(90)(120)
Total identifiable net assets/(liabilities) acquired53 465 (336)310 429 
Noncontrolling interest— — — (151)— 
Goodwill
307 578 3,124 910 784 
Total net assets acquired
$360 $1,043 $2,788 $1,069 $1,213 
(1)    The weighted-average useful life of customer intangibles ranges from 10 years to 20 years.
(2)    The weighted-average useful life of trade names ranges from 2 years to 10 years.
(3)    The weighted-average useful life of developed technology and other is 8 years.
(4)    The weighted-average useful life of non-competition agreements is 4 years.
v3.25.2
Restructuring and Employee Severance (Tables)
 12 Months Ended
Jun. 30, 2025
Restructuring Charges [Abstract]  
Summary of Restructuring and Employee Severance
The following table summarizes restructuring and employee severance costs:
(in millions)202520242023
Employee-related costs $61 $95 $39 
Facility exit and other costs 27 80 56 
Total restructuring and employee severance$88 $175 $95 
Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance
The following table summarizes activity related to liabilities associated with restructuring and employee severance:
(in millions)Employee-
Related Costs		Facility Exit
and Other Costs		Total
Balance at June 30, 2023$44 $2 $46 
Additions74 13 87 
Payments and other adjustments(26)(10)(36)
Balance at June 30, 202492 5 97 
Additions40 — 40 
Payments and other adjustments(53)(5)(58)
Balance at June 30, 2025$79 $— $79 
v3.25.2
Goodwill and Other Intangible Assets (Tables)
 12 Months Ended
Jun. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill by Reportable Segment
The following table summarizes the changes in the carrying amount of goodwill for the two reportable segments and the remaining operating segments, included in Other and in total:
(in millions)Pharmaceutical and Specialty Solutions
Global Medical Products and Distribution (1)
Other
(2) (3)
Total
Balance at June 30, 2023$2,762 $681 $1,170 $4,613 
Goodwill acquired, net of purchase price adjustments793 (3)— 790 
Foreign currency translation adjustments and other— (3)— (3)
Goodwill Impairment— (675)— (675)
Balance at June 30, 2024$3,555 $— $1,170 $4,725 
Goodwill acquired, net of purchase price adjustments4,389 — 578 4,967 
Foreign currency translation adjustments and other(1)— — (1)
Balance at June 30, 2025$7,943 $— $1,748 $9,691 
(1)    At June 30, 2025 and 2024, the GMPD segment accumulated goodwill impairment loss was $5.4 billion.
(2)    At June 30, 2025 and 2024, the Nuclear and Precision Health Solutions accumulated goodwill impairment loss was $829 million.
(3)    Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics.

The increase in the Pharma segment goodwill is primarily due to the GIA and ION acquisitions that occurred during fiscal 2025. The increase in the Other segment goodwill is due to the ADS acquisition that occurred during fiscal 2025. Goodwill recognized in connection with these acquisitions primarily represent the expected benefits from the expected growth from new customers, the assembled workforce of the acquired entities, and synergies of integrating these businesses. Substantially all of the goodwill recorded is expected to be nondeductible for income tax purposes.
During fiscal 2025, we did not identify any indicators of impairment within our reporting units.
We performed interim quantitative goodwill impairment testing for GMPD at September 30, 2023 and March 31, 2024, which resulted in pre-tax goodwill impairment charges of $585 million and $90 million, respectively. GMPD goodwill was fully impaired during the third quarter of fiscal 2024. During fiscal 2023, GMPD had cumulative pre-tax impairment charges of $1.2 billion. These goodwill impairment charges are recorded in impairments and
(gain)/loss on disposal of assets, net in our consolidated statements of earnings.
In connection with the divestiture of the Outcomes business, during fiscal 2023, we allocated and reclassified $24 million of goodwill from the Pharma operating segment to the Outcomes disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that was retained.
Schedule of Finite-Lived Intangible Assets
The following tables summarize other intangible assets by class at June 30:
2025
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible		Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents$13 $— $13 N/A
Total indefinite-life intangibles13 — 13 N/A
Definite-life intangibles:
Customer intangibles
3,876 2,639 1,237 11
Trademarks, trade names, and patents
1,340 459 881 8
Developed technology and other1,030 726 304 6
Non-Competition Agreements72 21 51 4
Total definite-life intangibles6,318 3,845 2,473 10
Total other intangible assets$6,331 $3,845 $2,486 N/A
2024
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible
Indefinite-life intangibles:
Trademarks and patents$12 $— $12 
Total indefinite-life intangibles12 — 12 
Definite-life intangibles:
Customer intangibles
3,628 2,431 1,197 
Trademarks, trade names, and patents
561 408 153 
Developed technology and other1,047 684 363 
Total definite-life intangibles5,236 3,523 1,713 
Total other intangible assets$5,248 $3,523 $1,725 
Schedule of Indefinite-Lived Intangible Assets
The following tables summarize other intangible assets by class at June 30:
2025
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible		Weighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents$13 $— $13 N/A
Total indefinite-life intangibles13 — 13 N/A
Definite-life intangibles:
Customer intangibles
3,876 2,639 1,237 11
Trademarks, trade names, and patents
1,340 459 881 8
Developed technology and other1,030 726 304 6
Non-Competition Agreements72 21 51 4
Total definite-life intangibles6,318 3,845 2,473 10
Total other intangible assets$6,331 $3,845 $2,486 N/A
2024
(in millions)Gross
Intangible		Accumulated
Amortization		Net
Intangible
Indefinite-life intangibles:
Trademarks and patents$12 $— $12 
Total indefinite-life intangibles12 — 12 
Definite-life intangibles:
Customer intangibles
3,628 2,431 1,197 
Trademarks, trade names, and patents
561 408 153 
Developed technology and other1,047 684 363 
Total definite-life intangibles5,236 3,523 1,713 
Total other intangible assets$5,248 $3,523 $1,725 
v3.25.2
Leases (Tables)
 12 Months Ended
Jun. 30, 2025
Leases [Abstract]  
Schedule of Lease Costs
The following table summarizes the components of lease cost:
(in millions)202520242023
Operating lease cost$157 $120 $112 
Finance lease cost51 39 31 
Variable lease cost43 31 21 
Total lease cost$251 $190 $164 
Leases Supplemental Balance Sheet Information
The following table summarizes supplemental balance sheet and other information related to leases at June 30:
(in millions)
20251
2024
Operating Leases
Operating lease right-of-use assets$758 $475 
Current portion of operating lease liabilities164 117 
Long-term operating lease liabilities654 400 
Total operating lease liabilities818 517 
Finance Leases
Finance lease right-of-use assets192 102 
Current portion of finance lease liabilities44 33 
Long-term finance lease liabilities157 75 
Total finance lease liabilities$201 $108 
Weighted-average remaining lease term (years)
Operating leases5.9 years5.5 years
Finance leases6.3 years4.1 years
Weighted-average discount rate
Operating leases3.9 %4.1 %
Finance leases4.6 %4.4 %
1 Increases in the right-of-use asset and liability balances are primarily due to acquisitions.
Leases Supplemental Cash Flow Information
The following table summarizes supplemental cash flow information related to leases:
(in millions)202520242023
Cash paid for lease liabilities:
Operating cash flows paid for operating leases$167 $124 $119 
Financing cash flows paid for finance leases53 36 31 
Non-cash right-of-use assets obtained in exchange for lease obligations:
New operating leases130 143 75 
New finance leases107 55 42 
Schedule of Future Lease Payments for Operating Leases
Future lease payments under non-cancellable leases as of June 30, 2025 were as follows:
(in millions)Operating LeasesFinance LeasesTotal
2026$197 $52 $249 
2027174 45 219 
2028146 35 181 
2029111 25 136 
203097 19 116 
Thereafter199 57 256 
Total future lease payments924 233 1,157 
Less: imputed interest106 32 138 
Total lease liabilities$818 $201 $1,019 
Schedule of Future Lease Payments for Finance Leases
Future lease payments under non-cancellable leases as of June 30, 2025 were as follows:
(in millions)Operating LeasesFinance LeasesTotal
2026$197 $52 $249 
2027174 45 219 
2028146 35 181 
2029111 25 136 
203097 19 116 
Thereafter199 57 256 
Total future lease payments924 233 1,157 
Less: imputed interest106 32 138 
Total lease liabilities$818 $201 $1,019 
v3.25.2
Long-Term Obligations and Other Short-Term Borrowings (Tables)
 12 Months Ended
Jun. 30, 2025
Debt Disclosure [Abstract]  
Schedule of Debt
The following table summarizes long-term obligations and other short-term borrowings at June 30:
(in millions) (1)20252024
3.5% Notes due 2024— 401 
3.75% Notes due 2025501 507 
4.7% Notes due 2026498 — 
3.41% Notes due 20271,206 1,191 
5.125% Notes due 2029645 644 
5.0% Notes due 2029745 — 
5.45% Notes due 2034501 491 
5.35% Notes due 2034989 — 
4.6% Notes due 2043323 308 
4.5% Notes due 2044338 330 
4.9% Notes due 2045438 423 
4.368% Notes due 2047566 563 
5.75% Notes due 2054641 — 
7.0% Debentures due 2026124 124 
Floating Rate Term Loan due 2028799 — 
Other Obligations213 110 
Total8,527 5,092 
Less: current portion of long-term obligations and other short-term borrowings550 434 
Long-term obligations, less current portion$7,977 $4,658 
(1)    Maturities are presented on a calendar year basis.
v3.25.2
Income Taxes (Tables)
 12 Months Ended
Jun. 30, 2025
Income Tax Disclosure [Abstract]  
Schedule of Income Before Income Tax, Domestic and Foreign
The following table summarizes earnings before income taxes:
(in millions)202520242023
U.S. operations$1,715 $892 $316 
Non-U.S. operations386 309 347 
Earnings before income taxes
$2,101 $1,201 $663 
Schedule of Components of Income Tax Expense (Benefit), Current and Deferred
The following table summarizes the components of provision for/(benefit from) income taxes:
(in millions)202520242023
Current:
Federal$135 $305 $219 
State and local72 68 69 
Non-U.S.82 79 84 
Total current$289 $452 $372 
Deferred:
Federal$205 $(89)$(23)
State and local39 12 11 
Non-U.S.(1)(27)(28)
Total deferred$243 $(104)$(40)
Provision for income taxes
$532 $348 $332 
Schedule of Effective Income Tax Rate Reconciliation
The following table presents a reconciliation of the provision based on the federal statutory income tax rate to our effective income tax rate:
 202520242023
Provision at Federal statutory rate21.0 %21.0 %21.0 %
State and local income taxes, net of federal benefit4.0 3.1 6.5 
Tax effect of foreign operations0.2 (1.6)(5.4)
Nondeductible/nontaxable items0.7 (0.1)(1.1)
Impact of Divestitures— — (1.9)
Withholding Taxes0.3 1.0 1.0 
Change in Valuation Allowances0.1 (1.1)(5.1)
US Taxes on International Income (1)
(1.3)(2.1)0.6 
Impact of Resolutions with IRS and other related matters (0.1)0.4 0.3 
Opioid litigation0.2 1.0 0.1 
Goodwill Impairment— 8.7 33.8 
Specialty Alliance Share-based Compensation
1.4 — — 
Other (1.2)(1.4)0.2 
Effective income tax rate25.3 %28.9 %50.0 %
(1) Includes the tax impact of the Foreign-Derived Intangible Income ("FDII") deduction offset by Global Intangible Low-Taxed Income ("GILTI") tax, and other foreign income that is taxable under the U.S. tax code.
Schedule of Deferred Tax Assets and Liabilities
The following table presents the components of the deferred income tax assets and liabilities at June 30:
(in millions)20252024
Deferred income tax assets:
Receivable basis difference$26 $81 
Accrued liabilities651 749 
Share-based compensation23 28 
Loss and tax credit carryforwards386 512 
Deferred tax assets related to uncertain tax positions47 45 
Other97 76 
Total deferred income tax assets1,230 1,491 
Valuation allowance for deferred income tax assets(254)(300)
Net deferred income tax assets$976 $1,191 
Deferred income tax liabilities:
Inventory basis differences$(1,103)$(1,122)
Property-related(358)(350)
Goodwill and other intangibles(834)(710)
Self-Insurance(981)(981)
Total deferred income tax liabilities$(3,276)$(3,163)
Net deferred income tax liability
$(2,300)$(1,972)
Schedule of Deferred Tax Assets and Liabilities after Netting by Tax Jurisdiction
Deferred income tax assets and liabilities in the preceding table, after netting by taxing jurisdiction and for uncertain tax positions, are in the following captions in the consolidated balance sheets at June 30:
(in millions)20252024
Noncurrent deferred income tax asset (1)$64 $72 
Noncurrent deferred income tax liability (2)(2,364)(2,044)
Net deferred income tax liability$(2,300)$(1,972)
(1)Included in other assets in the consolidated balance sheets.
(2)Included in deferred income taxes and other liabilities in the consolidated balance sheets.
Schedule of Unrecognized Tax Benefits Roll Forward The following table presents a reconciliation of the beginning and ending amounts of unrecognized tax benefits:
(in millions)202520242023
Balance at beginning of fiscal year$981 $1,015 $948 
Additions for tax positions of the current year8 30 25 
Additions for tax positions of prior years15 28 133 
Reductions for tax positions of prior years(101)(87)(16)
Settlements with tax authorities (22)(3)(73)
Expiration of the statute of limitations (2)(2)(2)
Balance at end of fiscal year
$879 $981 $1,015 
v3.25.2
Fair Value Measurements (Tables)
 12 Months Ended
Jun. 30, 2025
Fair Value Disclosures [Abstract]  
Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables present the fair values for assets and (liabilities) measured on a recurring basis at June 30:
2025
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,672 $— $— $1,672 
Other investments (1)108 — — 108 
Liabilities:
Forward contracts (2)— (48)— (48)
Share-based awards (3)— — (843)(843)
2024
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,442 $— $— $1,442 
Other investments (1)108 — — 108 
Liabilities:
Forward contracts (2)— (87)— (87)
(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high-quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.
(2)The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance
risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the consolidated balance sheets.
(3)The shared-based awards are comprised of liability-classified awards, as defined under ASC 718, resulting from the acquisition of GIA. The fair value of the GIA Units is determined using the discounted cash flow method. These are presented in deferred income taxes and other liabilities within the consolidated balance sheets. See Note 15 for additional information.
v3.25.2
Financial Instruments (Tables)
 12 Months Ended
Jun. 30, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Value of Assets and Liabilities Related to Derivatives Designated as Hedging Instruments
The following table summarizes the fair value of our assets and liabilities related to derivatives designated as hedging instruments and the respective line items in which they were recorded in the consolidated balance sheets at June 30:
(in millions)20252024
Assets:
Cross-currency swap (1)$— $12 
Foreign currency contracts (1)6 1 
Pay-floating interest rate swaps (1)14 3 
Total assets$20 $16 
Liabilities:
Cross-currency swap (2)$24 $1 
Foreign currency contracts (2)1 8 
Pay-floating interest rate swaps (2)43 94 
Total liabilities$68 $103 
(1)    Included in other assets in the consolidated balance sheets.
(2)    Included in deferred income taxes and other liabilities in the consolidated balance sheets.
Derivative [Line Items]  
Schedule of Gain/(Loss) Included in AOCI for Derivative Instruments
The following table summarizes the pre-tax gain/(loss) included in OCI for derivative instruments designated as cash flow hedges:
(in millions)202520242023
Foreign currency contracts$11 $(7)$(2)
Schedule of Gain/(Loss) Recognized in Earnings for Interest Rate Contracts Designated as Fair Value Hedges
The following table summarizes the gain/(loss) recognized in earnings for interest rate swaps designated as fair value hedges:
(in millions)202520242023
Pay-floating interest rate swaps (1)$51 $2 $(50)
Fixed-rate debt (1)(51)(2)50 
(1)     Included in interest expense, net in the consolidated statements of earnings.
Schedule of Gain/(Loss) Reclassified from AOCI into Earnings for Derivative Instruments Designated as Cash Flow Hedges
The following table summarizes the pre-tax gain/(loss) reclassified from AOCI into earnings for derivative instruments designated as cash flow hedges:
(in millions)202520242023
Foreign currency contracts (1)$3 $1 $9 
Foreign currency contracts (2)(6)4 2 
Foreign currency contracts (3)(1)— 1 
Forward interest rate swaps (4)2 2 2 
(1)    Included in revenue in the consolidated statements of earnings.
(2)    Included in cost of products sold in the consolidated statements of earnings.
(3)    Included in SG&A expenses in the consolidated statements of earnings.
(4)    Included in interest expense, net in the consolidated statements of earnings.
Schedule of Gain/(Loss) Recognized in Earnings for Economic (Non-designated) Derivative Instruments
The following table summarizes the gain/(loss) recognized in earnings for economic (non-designated) derivative instruments:
(in millions)202520242023
Foreign currency contracts
$(6)$1 $(7)
Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount
The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at June 30:
(in millions)20252024
Estimated fair value$8,388 $4,891 
Carrying amount8,527 5,092 
Schedule of Fair Value Gain/(Loss) Derivative Instrument
The following table is a summary of the fair value gain/(loss) of our derivative instruments based upon the estimated amount that we would receive (or pay), considering counter-party credit risk, to terminate the contracts at June 30:
20252024
(in millions)Notional
Amount		Fair Value
Gain/(Loss)		Notional
Amount		Fair Value
Gain/(Loss)
Pay-floating interest rate swaps$1,600 $(29)$1,600 $(91)
Foreign currency contracts575 5 579 (7)
Cross-currency swap332 (24)334 11 
Not Designated as Hedging Instrument  
Derivative [Line Items]  
Schedule of Outstanding Instruments
The following tables summarize the outstanding economic (non-designated) derivative instruments at June 30:
 2025
(in millions)Notional AmountMaturity Date
Foreign currency contracts$194 Jul 2025
 2024
(in millions)Notional AmountMaturity Date
Foreign currency contracts$178 Jul 2024
Fair Value Hedging  
Derivative [Line Items]  
Schedule of Outstanding Instruments
The following tables summarize the outstanding interest rate swaps designated as fair value hedges at June 30, 2025 and 2024:
(in millions)Notional AmountMaturity Date
Pay-floating interest rate swaps$1,600 Jun 2027-Feb 2031
Cash Flow Hedging  
Derivative [Line Items]  
Schedule of Outstanding Instruments
The following tables summarize the outstanding cash flow hedges at June 30:
 2025
(in millions)Notional AmountMaturity Date
Foreign currency contracts$381 Jul 2025-Jun 2026
 2024
(in millions)Notional AmountMaturity Date
Foreign currency contracts$401 Jul 2024-Jun 2025
v3.25.2
Shareholders' Equity (Tables)
 12 Months Ended
Jun. 30, 2025
Equity [Abstract]  
Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total
The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)Foreign
Currency
Translation
Adjustments and Other		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2023$(137)$(14)$(151)
Other comprehensive loss, before reclassifications(1)(7)(8)
Amounts reclassified to earnings— (8)(8)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $5 million
(1)(15)(16)
Balance at June 30, 2024(138)(29)(167)
Other comprehensive income/(loss), before reclassifications(3)13 10 
Amounts reclassified to earnings— 2 2 
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax benefit of $6 million
(3)15 12 
Balance at June 30, 2025$(141)$(14)$(155)
v3.25.2
Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)
 12 Months Ended
Jun. 30, 2025
Earnings Per Share [Abstract]  
Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share
The following table reconcile the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc. ("EPS"):
(in millions, except per share amounts)202520242023
Net earnings
$1,569 $853 $331 
Net earnings attributable to noncontrolling interest(8)(1)(1)
Net earnings attributable to Cardinal Health, Inc.
$1,561 $852 $330 
Weighted-average common shares–basic241 245 261 
Effect of dilutive securities:
Employee stock options, restricted share units, and performance share units
1 2 1 
Weighted-average common shares–diluted242 247 262 
Basic earnings per common share attributable to Cardinal Health, Inc.:
$6.48 $3.48 $1.27 
Diluted earnings per common share attributable to Cardinal Health, Inc.:
6.45 3.45 1.26 
v3.25.2
Segment Information (Tables)
 12 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Revenue by Reportable Segment
The following table presents revenue for the two reportable segments and disaggregated revenue within the remaining operating segments, included in Other, and Corporate:
(in millions)202520242023
Pharmaceutical and Specialty Solutions$204,644 $210,019 $188,814 
Global Medical Products and Distribution12,636 12,381 12,222 
Nuclear and Precision Health Solutions1,578 1,369 1,197 
at-Home Solutions3,480 2,869 2,584 
OptiFreight® Logistics
324 274 240 
Other5,382 4,512 4,021 
Total segment revenue222,662 226,912 205,057 
Corporate (1)(84)(85)(78)
Total revenue$222,578 $226,827 $204,979 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Disaggregation of Revenue [Table Text Block]
(in millions)202520242023
Pharmaceutical and Specialty Solutions$204,644 $210,019 $188,814 
Global Medical Products and Distribution12,636 12,381 12,222 
Nuclear and Precision Health Solutions1,578 1,369 1,197 
at-Home Solutions3,480 2,869 2,584 
OptiFreight® Logistics
324 274 240 
Other5,382 4,512 4,021 
Total segment revenue222,662 226,912 205,057 
Corporate (1)(84)(85)(78)
Total revenue$222,578 $226,827 $204,979 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Revenue from External Customers by Geographic Areas [Table Text Block]
The following table presents revenue by geographic area:
(in millions)202520242023
United States$220,993 $225,231 $203,440 
International1,669 1,681 1,617 
Total segment revenue222,662 226,912 205,057 
Corporate (1)(84)(85)(78)
Total revenue$222,578 $226,827 $204,979 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment
The following tables present revenue, expenses, and segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
2025
(in millions)PharmaGMPDOther Total
Segment revenue
$204,644 $12,636 $5,382 $222,662 
Cost of products sold
199,999 10,470 4,023 214,492 
SG&A2,387 2,031 843 5,261 
Total segment expenses
202,386 12,501 4,866 219,753 
Segment profit$2,258 $135 $516 $2,909 
Corporate (1)(634)
Consolidated operating earnings
$2,275 
2024
(in millions)PharmaGMPDOther Total
Segment revenue
$210,019 $12,381 $4,512 $226,912 
Cost of products sold
205,864 10,264 3,367 219,495 
SG&A2,140 2,025 722 4,887 
Total segment expenses
208,004 12,289 4,089 224,382 
Segment profit$2,015 $92 $423 $2,530 
Corporate (1)(1,287)
Consolidated operating earnings
$1,243 
2023
(in millions)PharmaGMPDOther Total
Segment revenue$188,814 $12,222 $4,021 $205,057 
Cost of products sold184,814 10,377 2,990 198,181 
SG&A2,119 1,992 635 4,746 
Total segment expenses186,933 12,369 3,625 202,927 
Segment profit$1,881 $(147)$396 $2,130 
Corporate (1)(1,378)
Consolidated operating earnings$752 
(1)Corporate revenue and expenses consists of the elimination of inter-segment revenue and other revenue and expenses not allocated to the segments.
Depreciation and Amortization and Additions to Property and Equipment by Reportable Segment
The following tables present depreciation and amortization and additions to property and equipment for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
(in millions)202520242023
Pharmaceutical and Specialty Solutions$185 $184 $194 
Global Medical Products and Distribution212 205 173 
Other88 79 71 
Corporate305 242 254 
Total depreciation and amortization$790 $710 $692 

(in millions)202520242023
Pharmaceutical and Specialty Solutions$118 $76 $56 
Global Medical Products and Distribution133 136 191 
Other88 81 52 
Corporate208 218 182 
Total additions to property and equipment$547 $511 $481 
Assets by Reportable Segment
The following table presents total assets for the two reportable segments and the remaining operating segments, included in Other, and Corporate at June 30:
(in millions)20252024
Pharmaceutical and Specialty Solutions$37,313 $29,149 
Global Medical Products and Distribution
6,889 7,047 
Other4,045 2,606 
Corporate4,875 6,319 
Total assets$53,122 $45,121 
Property and Equipment, Net by Geographic Area
The following table presents property and equipment, net by geographic area:
(in millions)20252024
United States$2,422 $2,106 
International436 423 
Property and equipment, net$2,858 $2,529 
v3.25.2
Share-Based Compensation (Tables)
 12 Months Ended
Jun. 30, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Total Share-based Compensation Expense by Type of Award
The following table provides total share-based compensation expense by type of award:
(in millions)202520242023
Restricted share unit expense$71 $77 $64 
Performance share unit expense50 44 32 
Total share-based compensation expense
$121 $121 $96 
Schedule of Transactions Related to Restricted Share Units Under the Plans
The following table summarizes all transactions related to restricted share units under the Plans:
(in millions, except per share amounts)Restricted Share UnitsWeighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20232.2 $57.37 
Granted0.9 91.06 
Vested(1.2)60.47 
Canceled and forfeited(0.2)74.40 
Nonvested at June 30, 20241.7 70.98 
Granted0.7 108.72 
Vested(0.9)72.07 
Canceled and forfeited(0.1)94.67 
Nonvested at June 30, 20251.4 $86.30 
Additional Restricted Shares and Restricted Share Units Activity
The following table provides additional data related to restricted share unit activity:
(in millions)202520242023
Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax$64 $71 $73 
Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years)222
Total fair value of shares vested during the year$60 $63 $58 
Schedule of Transactions Related to Performance Share Units Under the Plans
The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):
(in millions, except per share amounts)Performance
Share Units		Weighted-Average
Grant Date Fair
Value per Share
Nonvested at June 30, 20231.2 $82.17 
Granted0.5 94.66 
Vested(0.4)62.26 
Canceled and forfeited— — 
Nonvested at June 30, 20241.3 97.03 
Granted0.5 113.88 
Vested(0.3)108.79 
Canceled and forfeited— — 
Nonvested at June 30, 20251.5 $99.45 
Additional Data Related to Performance Share Units Activity
The following table provides additional data related to performance share unit activity:
(in millions)202520242023
Total compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized, pre-tax$47 $46 $38 
Weighted-average period over which performance share unit cost is expected to be recognized (in years)222
Total fair value of shares vested during the year$49 $20 $23 
Share-Based Payment Arrangement, Activity
The following table summarizes the fair market value of the GIA Units as of June 30, 2025:
(in millions, except per share amounts)
GIA Share Units
Fair Value
per Share
Nonvested at January 30, 2025216 $1.46 
Granted61 1.46 
Vested(56)1.46 
Canceled and forfeited(1)1.46 
Nonvested at June 30, 2025220 $1.54 
Vested at June 30, 2025
548 $1.54 
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Receivables) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Allowance for doubtful accounts $ 662 $ 677 $ 720 $ 832
Finance notes and related accrued interest, net, total 32 43    
Finance notes and related accrued interest, net, current $ 7 14    
Minimum        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Receivable financing agreement term 1 year      
Maximum        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Receivable financing agreement term 5 years      
SEC Schedule, 12-09, Allowance, Credit Loss [Member]        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Allowance for doubtful accounts $ 213 233 240 207
SEC Schedule, 12-09, Allowance, Loss on Finance Receivable [Member]        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Allowance for doubtful accounts $ 2 $ 3 $ 6 $ 8
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Revenue and Gross Trade Receivables Percentage by Major Customers) (Details) - Pharmaceutical and Specialty Solutions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
CVS Health Corporation      
Revenue, Major Customer [Line Items]      
Percent of Gross Trade Receivables 26.00% 22.00%  
CVS Health Corporation | Revenue Benchmark | Customer Concentration Risk      
Revenue, Major Customer [Line Items]      
Concentration Risk, Percentage 30.00% 24.00% 25.00%
OptumRx [Member]      
Revenue, Major Customer [Line Items]      
Percent of Gross Trade Receivables 0.00% 6.00%  
OptumRx [Member] | Revenue Benchmark | Customer Concentration Risk      
Revenue, Major Customer [Line Items]      
Concentration Risk, Percentage 0.00% 17.00% 16.00%
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Major Customers) (Details) - organization
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Concentration Risk [Line Items]      
Largest group purchasing organizations 2    
Group Purchasing Organizations | Revenue Benchmark | Customer Concentration Risk      
Concentration Risk [Line Items]      
Revenue, major customer, percentage 27.00% 16.00% 15.00%
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Inventories) (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Accounting Policies [Abstract]    
Portion of inventories held at LIFO, percentage 52.00% 50.00%
Inventory Reserve Excess and Obsolete [Member]    
Inventory Reserve Table [Line Items]    
Reserves for excess and obsolete inventory $ 132 $ 149
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Property and Equipment) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Property, Plant and Equipment [Line Items]      
Depreciation $ 488 $ 470 $ 441
Interest rate on long-term projects (approximates weighted-average on long-term obligations) 5.00%    
Building and Improvements | Minimum      
Property, Plant and Equipment [Line Items]      
Useful life of property and equipment 3 years    
Building and Improvements | Maximum      
Property, Plant and Equipment [Line Items]      
Useful life of property and equipment 39 years    
Machinery and equipment | Minimum      
Property, Plant and Equipment [Line Items]      
Useful life of property and equipment 3 years    
Machinery and equipment | Maximum      
Property, Plant and Equipment [Line Items]      
Useful life of property and equipment 20 years    
Capitalized software held for internal use | Minimum      
Property, Plant and Equipment [Line Items]      
Useful life of property and equipment 3 years    
Capitalized software held for internal use | Maximum      
Property, Plant and Equipment [Line Items]      
Useful life of property and equipment 7 years    
Furniture and fixtures | Minimum      
Property, Plant and Equipment [Line Items]      
Useful life of property and equipment 3 years    
Furniture and fixtures | Maximum      
Property, Plant and Equipment [Line Items]      
Useful life of property and equipment 7 years    
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Components of Property and Equipment) (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Property, Plant and Equipment [Line Items]    
Total property and equipment, at cost $ 7,516 $ 6,695
Total property and equipment, at cost (4,658) (4,166)
Property and equipment, net 2,858 2,529
Land, building, and improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment, at cost 2,178 1,879
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment, at cost 2,685 2,367
Capitalized software held for internal use    
Property, Plant and Equipment [Line Items]    
Total property and equipment, at cost 1,940 1,744
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Total property and equipment, at cost 136 128
Construction in Progress    
Property, Plant and Equipment [Line Items]    
Total property and equipment, at cost $ 577 $ 577
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Goodwill and Other Intangible Assets) (Details) - USD ($)
 3 Months Ended 12 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2025
Goodwill and Intangible Assets [Line Items]          
Goodwill impairment loss     $ 675,000,000    
GMPD          
Goodwill and Intangible Assets [Line Items]          
Goodwill impairment loss $ 90,000,000 $ 585,000,000 $ 675,000,000 $ 1,200,000,000  
Goodwill, Impairment Loss, Statement of Income or Comprehensive Income [Extensible Enumeration]     Operating Income (Loss) Operating Income (Loss)  
Minimum          
Goodwill and Intangible Assets [Line Items]          
Discount Rate, fair value inputs         9.50%
Maximum          
Goodwill and Intangible Assets [Line Items]          
Discount Rate, fair value inputs         11.00%
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Leases) (Details)
Jun. 30, 2025
Minimum  
Operating Leased Assets [Line Items]  
Lease term of the contract 1 year
Maximum  
Operating Leased Assets [Line Items]  
Lease term of the contract 17 years
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Vendor Reserves) (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Accounting Policies [Abstract]    
Vendor reserves $ 96 $ 112
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies Loss Contingencies (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2023
Jun. 30, 2025
Product Liability Lawsuits | Minimum    
Loss Contingencies [Line Items]    
Loss contingency accrual   $ 56
Total Opioid Litigation [Member]    
Loss Contingencies [Line Items]    
Litigation settlement $ 5,600  
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Share-Based Compensation) (Details) - Performance Share Units
 12 Months Ended
Jun. 30, 2025
Rate
Minimum  
Schedule of Share-Based Payment Valuation Assumptions [Line Items]  
Target performance goal (as a percent) 0.00%
Maximum  
Schedule of Share-Based Payment Valuation Assumptions [Line Items]  
Target performance goal (as a percent) 240.00%
August 2021  
Schedule of Share-Based Payment Valuation Assumptions [Line Items]  
Risk Free Interest Rate 3.12%
Expected Volatility 32.41%
August 2022  
Schedule of Share-Based Payment Valuation Assumptions [Line Items]  
Risk Free Interest Rate 5.13%
Expected Volatility 26.58%
September 2023  
Schedule of Share-Based Payment Valuation Assumptions [Line Items]  
Risk Free Interest Rate 4.66%
Expected Volatility 23.99%
August 2023  
Schedule of Share-Based Payment Valuation Assumptions [Line Items]  
Risk Free Interest Rate 3.89%
Expected Volatility 24.54%
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Dividends) (Details) - $ / shares
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Accounting Policies [Abstract]      
Cash dividends per common share (in usd per share) $ 2.02 $ 2.00 $ 1.98
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Sales Returns and Allowances) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Accounting Policies [Abstract]    
Accrual for estimated sales returns and allowances $ 447 $ 441
Returns and allowances $ 2,200  
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Shipping and Handling) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Distribution, selling, general and administrative expenses [Line Items]      
Distribution, selling, general, and administrative expenses $ 5,382 $ 5,000 $ 4,800
Shipping and Handling [Member]      
Distribution, selling, general and administrative expenses [Line Items]      
Distribution, selling, general, and administrative expenses $ 909 $ 866 $ 835
v3.25.2
Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Variable Interest Entity [Line Items]    
Total assets $ 53,122 $ 45,121
Variable Interest Entity, Primary Beneficiary [Member]    
Variable Interest Entity [Line Items]    
Total assets 601  
Liabilities $ 187  
v3.25.2
Business Combinations and Asset Acquisitions (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Jan. 30, 2025
Dec. 02, 2024
Jun. 30, 2023
Business Acquistion [Line Items]                
Net Intangible $ 2,473     $ 2,473 $ 1,713      
Goodwill $ 9,691     $ 9,691 4,725     $ 4,613
Weighted- Average Remaining Amortization Period (Years) 10 years     10 years        
Minimum                
Business Acquistion [Line Items]                
Discount Rate, fair value inputs 9.50%     9.50%        
Maximum                
Business Acquistion [Line Items]                
Discount Rate, fair value inputs 11.00%     11.00%        
Trademarks, trade names, and patents                
Business Acquistion [Line Items]                
Net Intangible $ 881     $ 881 153      
Weighted- Average Remaining Amortization Period (Years) 8 years     8 years        
Developed Technology Rights [Member]                
Business Acquistion [Line Items]                
Net Intangible $ 304     $ 304 363      
Weighted- Average Remaining Amortization Period (Years) 6 years     6 years        
Noncompete Agreements                
Business Acquistion [Line Items]                
Net Intangible $ 51     $ 51        
Weighted- Average Remaining Amortization Period (Years) 4 years     4 years        
Customer-Related Intangible Assets                
Business Acquistion [Line Items]                
Net Intangible $ 1,237     $ 1,237 1,197      
Weighted- Average Remaining Amortization Period (Years) 11 years     11 years        
Specialty Networks                
Business Acquistion [Line Items]                
Payments to Acquire Businesses, Gross     $ 1,200          
Business Combination, Acquisition-Related Cost, Expense       $ 7 $ 16      
Total identifiable intangible assets acquired $ 520     520        
Cash and equivalents 23     23        
Trade receivables, net 17     17        
Trade expense and Others 2     2        
Other accrued liabilities (13)     (13)        
Deferred income taxes and other liabilities (120)     (120)        
Total identifiable net assets/(liabilities) acquired 429     429        
Goodwill 784     784        
Total net assets acquired 1,213     $ 1,213        
Business Combination, Recognized Asset Acquired, Other Asset, Noncurrent             $ 0  
Business Combination, Recognized Liability Assumed, Long-Term Debt, Current             0  
Business Combination, Recognized Liability Assumed, Accounts Payable, Current             0  
Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment             0  
Business Combination, Recognized Asset Acquired, Inventory, Current             0  
Business Combination, Recognized Liability Assumed, Long-Term Debt, Noncurrent             0  
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value             0  
Specialty Networks | Minimum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow                
Business Acquistion [Line Items]                
Intangible Assets Measurement Input         700.00%      
Specialty Networks | Maximum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow                
Business Acquistion [Line Items]                
Intangible Assets Measurement Input       20.00%        
Specialty Networks | Trademarks, trade names, and patents                
Business Acquistion [Line Items]                
Net Intangible $ 15     $ 15        
Specialty Networks | Trademarks, trade names, and patents | Minimum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 2 years     2 years        
Specialty Networks | Trademarks, trade names, and patents | Maximum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 10 years     10 years        
Specialty Networks | Developed Technology Rights [Member]                
Business Acquistion [Line Items]                
Net Intangible $ 20     $ 20        
Weighted- Average Remaining Amortization Period (Years) 8 years     8 years        
Specialty Networks | Noncompete Agreements                
Business Acquistion [Line Items]                
Net Intangible $ 5     $ 5        
Weighted- Average Remaining Amortization Period (Years) 4 years     4 years        
Specialty Networks | Customer-Related Intangible Assets                
Business Acquistion [Line Items]                
Net Intangible $ 480     $ 480        
Specialty Networks | Customer-Related Intangible Assets | Minimum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 10 years     10 years        
Specialty Networks | Customer-Related Intangible Assets | Maximum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 20 years     20 years        
ION                
Business Acquistion [Line Items]                
Payments to Acquire Businesses, Gross $ 1,100              
Business Combination, Acquisition-Related Cost, Expense       $ 30        
Total identifiable intangible assets acquired 299     299        
Cash and equivalents 8     8        
Trade receivables, net 59     59        
Trade expense and Others 5     5        
Other accrued liabilities (39)     (39)        
Deferred income taxes and other liabilities (90)     (90)        
Total identifiable net assets/(liabilities) acquired 310     310        
Goodwill 910     910        
Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill, Less Noncontrolling Interest 1,069     $ 1,069        
Business Combination, Recognized Asset Acquired, Other Asset, Noncurrent             52  
Business Combination, Recognized Liability Assumed, Long-Term Debt, Current             (3)  
Business Combination, Recognized Liability Assumed, Accounts Payable, Current             (10)  
Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment             39  
Business Combination, Recognized Asset Acquired, Inventory, Current             4  
Business Combination, Recognized Liability Assumed, Long-Term Debt, Noncurrent             (14)  
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value             (151)  
ION | Minimum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow                
Business Acquistion [Line Items]                
Intangible Assets Measurement Input       700.00%        
ION | Maximum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow                
Business Acquistion [Line Items]                
Intangible Assets Measurement Input       20.00%        
ION | Trademarks, trade names, and patents                
Business Acquistion [Line Items]                
Net Intangible $ 73     $ 73        
ION | Trademarks, trade names, and patents | Minimum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 2 years     2 years        
ION | Trademarks, trade names, and patents | Maximum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 10 years     10 years        
ION | Developed Technology Rights [Member]                
Business Acquistion [Line Items]                
Net Intangible $ 0     $ 0        
ION | Noncompete Agreements                
Business Acquistion [Line Items]                
Net Intangible 0     0        
ION | Customer-Related Intangible Assets                
Business Acquistion [Line Items]                
Net Intangible $ 226     $ 226        
ION | Customer-Related Intangible Assets | Minimum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 10 years     10 years        
ION | Customer-Related Intangible Assets | Maximum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 20 years     20 years        
ADS                
Business Acquistion [Line Items]                
Payments to Acquire Businesses, Gross $ 1,100              
Business Combination, Acquisition-Related Cost, Expense       $ 31        
Total identifiable intangible assets acquired 500     500        
Cash and equivalents 14     14        
Trade receivables, net 97     97        
Trade expense and Others 8     8        
Other accrued liabilities (493)     (493)        
Deferred income taxes and other liabilities (12)     (12)        
Total identifiable net assets/(liabilities) acquired 465     465        
Goodwill 578     578        
Total net assets acquired 1,043     $ 1,043        
Business Combination, Recognized Asset Acquired, Other Asset, Noncurrent             376  
Business Combination, Recognized Liability Assumed, Long-Term Debt, Current             0  
Business Combination, Recognized Liability Assumed, Accounts Payable, Current             (104)  
Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment             1  
Business Combination, Recognized Asset Acquired, Inventory, Current             78  
Business Combination, Recognized Liability Assumed, Long-Term Debt, Noncurrent             0  
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value             0  
ADS | Minimum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow                
Business Acquistion [Line Items]                
Intangible Assets Measurement Input       700.00%        
ADS | Maximum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow                
Business Acquistion [Line Items]                
Intangible Assets Measurement Input       20.00%        
ADS | Trademarks, trade names, and patents                
Business Acquistion [Line Items]                
Net Intangible $ 28     $ 28        
ADS | Trademarks, trade names, and patents | Minimum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 2 years     2 years        
ADS | Trademarks, trade names, and patents | Maximum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 10 years     10 years        
ADS | Developed Technology Rights [Member]                
Business Acquistion [Line Items]                
Net Intangible $ 0     $ 0        
ADS | Noncompete Agreements                
Business Acquistion [Line Items]                
Net Intangible 0     0        
ADS | Customer-Related Intangible Assets                
Business Acquistion [Line Items]                
Net Intangible 472     472        
GIA                
Business Acquistion [Line Items]                
Payments to Acquire Businesses, Gross   $ 2,800            
Business Combination, Acquisition-Related Cost, Expense       75        
Total identifiable intangible assets acquired 223     223        
Cash and equivalents 53     53        
Trade receivables, net 191     191        
Trade expense and Others 14     14        
Other accrued liabilities (173)     (173)        
Deferred income taxes and other liabilities (947)     (947)        
Total identifiable net assets/(liabilities) acquired (336)     (336)        
Goodwill 3,124     3,124        
Total net assets acquired $ 2,788     $ 2,788        
Business Combination, Recognized Asset Acquired, Other Asset, Noncurrent             312  
Business Combination, Recognized Liability Assumed, Long-Term Debt, Current             (1)  
Business Combination, Recognized Liability Assumed, Accounts Payable, Current             (89)  
Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment             75  
Business Combination, Recognized Asset Acquired, Inventory, Current             21  
Business Combination, Recognized Liability Assumed, Long-Term Debt, Noncurrent             (15)  
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value             0  
Discount Rate, fair value inputs 9.50%     9.50%        
Business Combination, Voting Equity Interest Acquired, Percentage           73.00%    
Total fair value of shares vested during the year       $ 739        
GIA | Minimum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow                
Business Acquistion [Line Items]                
Intangible Assets Measurement Input       700.00%        
GIA | Maximum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow                
Business Acquistion [Line Items]                
Intangible Assets Measurement Input       20.00%        
GIA | Trademarks, trade names, and patents                
Business Acquistion [Line Items]                
Net Intangible $ 200     $ 200        
GIA | Trademarks, trade names, and patents | Minimum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 2 years     2 years        
GIA | Trademarks, trade names, and patents | Maximum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 10 years     10 years        
GIA | Developed Technology Rights [Member]                
Business Acquistion [Line Items]                
Net Intangible $ 0     $ 0        
GIA | Noncompete Agreements                
Business Acquistion [Line Items]                
Net Intangible $ 23     $ 23        
Weighted- Average Remaining Amortization Period (Years) 4 years     4 years        
GIA | Customer-Related Intangible Assets                
Business Acquistion [Line Items]                
Net Intangible $ 0     $ 0        
GIA | Customer-Related Intangible Assets | Minimum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 10 years     10 years        
GIA | Customer-Related Intangible Assets | Maximum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 20 years     20 years        
Urology America                
Business Acquistion [Line Items]                
Payments to Acquire Businesses, Gross $ 360              
Total identifiable intangible assets acquired 33     $ 33        
Cash and equivalents 4     4        
Trade receivables, net 24     24        
Trade expense and Others 3     3        
Other accrued liabilities (11)     (11)        
Deferred income taxes and other liabilities (46)     (46)        
Total identifiable net assets/(liabilities) acquired 53     53        
Goodwill 307     307        
Total net assets acquired 360     $ 360        
Business Combination, Recognized Asset Acquired, Other Asset, Noncurrent             41  
Business Combination, Recognized Liability Assumed, Long-Term Debt, Current             0  
Business Combination, Recognized Liability Assumed, Accounts Payable, Current             (20)  
Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment             28  
Business Combination, Recognized Asset Acquired, Inventory, Current             3  
Business Combination, Recognized Liability Assumed, Long-Term Debt, Noncurrent             (6)  
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value             $ 0  
Urology America | Minimum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow                
Business Acquistion [Line Items]                
Intangible Assets Measurement Input       700.00%        
Urology America | Maximum | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow                
Business Acquistion [Line Items]                
Intangible Assets Measurement Input       20.00%        
Urology America | Trademarks, trade names, and patents                
Business Acquistion [Line Items]                
Net Intangible $ 33     $ 33        
Urology America | Trademarks, trade names, and patents | Maximum                
Business Acquistion [Line Items]                
Weighted- Average Remaining Amortization Period (Years) 10 years     10 years        
Urology America | Developed Technology Rights [Member]                
Business Acquistion [Line Items]                
Net Intangible $ 0     $ 0        
Urology America | Noncompete Agreements                
Business Acquistion [Line Items]                
Net Intangible 0     0        
Urology America | Customer-Related Intangible Assets                
Business Acquistion [Line Items]                
Net Intangible $ 0     $ 0        
v3.25.2
Divestitures (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jul. 10, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Gain (Loss) on Sale of Assets and Asset Impairment Charges  
Outcomes Divestiture    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal $ (53)  
Transaction Data System Investment    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Equity ownership percentage 16.00%  
Transaction Data System Investment | Level 3 | Fair Value, Nonrecurring    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Equity Method Investments, Fair Value Disclosure   $ 147
v3.25.2
Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Restructuring Charges [Abstract]      
Employee-related costs $ 61 $ 95 $ 39
Facility Exit and Other Costs 27 80 56
Total restructuring and employee severance $ 88 $ 175 $ 95
v3.25.2
Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Restructuring Reserve [Roll Forward]    
Beginning Balance $ 97 $ 46
Additions 40 87
Payments and other adjustments (58) (36)
Ending Balance 79 97
Employee- Related Costs    
Restructuring Reserve [Roll Forward]    
Beginning Balance 92 44
Additions 40 74
Payments and other adjustments (53) (26)
Ending Balance 79 92
Facility Exit and Other Costs    
Restructuring Reserve [Roll Forward]    
Beginning Balance 5 2
Additions 0 13
Payments and other adjustments (5) (10)
Ending Balance $ 0 $ 5
v3.25.2
Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) - USD ($)
 3 Months Ended 12 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Goodwill [Roll Forward]          
Beginning balance     $ 4,725,000,000 $ 4,613,000,000  
Goodwill, Acquired During Period     4,967,000,000 790,000,000  
Foreign currency translation adjustments and other     1,000,000 3,000,000  
Goodwill impairment loss       675,000,000  
Ending balance $ 4,725,000,000   9,691,000,000 4,725,000,000 $ 4,613,000,000
GMPD          
Goodwill [Roll Forward]          
Beginning balance     0 681,000,000  
Goodwill, Acquired During Period     0 (3,000,000)  
Foreign currency translation adjustments and other     0 3,000,000  
Goodwill impairment loss 90,000,000 $ 585,000,000   675,000,000 1,200,000,000
Ending balance 0   0 0 681,000,000
Accumulated goodwill impairment loss 5,400,000,000     5,400,000,000  
Other Operating Segment          
Goodwill [Roll Forward]          
Beginning balance     1,170,000,000 1,170,000,000  
Goodwill, Acquired During Period     578,000,000 0  
Foreign currency translation adjustments and other     0 0  
Goodwill impairment loss       0  
Ending balance 1,170,000,000   1,748,000,000 1,170,000,000 1,170,000,000
Accumulated goodwill impairment loss 829,000,000   829,000,000 829,000,000  
Pharmaceutical and Specialty Solutions          
Goodwill [Roll Forward]          
Beginning balance     3,555,000,000 2,762,000,000  
Goodwill, Acquired During Period     4,389,000,000 793,000,000  
Foreign currency translation adjustments and other     1,000,000 0  
Goodwill impairment loss       0  
Ending balance 3,555,000,000   $ 7,943,000,000 3,555,000,000 $ 2,762,000,000
Pharmaceutical and Specialty Solutions | Outcomes Divestiture          
Goodwill [Roll Forward]          
Disposal Group, Including Discontinued Operation, Goodwill $ (24,000,000)     $ (24,000,000)  
v3.25.2
Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Indefinite-lived Intangible Assets [Line Items]      
Net Intangible $ 13 $ 12  
Finite-Lived Intangible Assets [Line Items]      
Amortization of Intangible Assets 303 264 $ 281
Gross Intangible 6,318 5,236  
Accumulated Amortization 3,845 3,523  
Net Intangible $ 2,473 1,713  
Weighted- Average Remaining Amortization Period (Years) 10 years    
Gross Intangible, Total other intangible assets $ 6,331 5,248  
Net Intangible, Total other intangible assets 2,486 1,725  
Trademarks and patents      
Indefinite-lived Intangible Assets [Line Items]      
Net Intangible 13 12  
Customer-Related Intangible Assets      
Finite-Lived Intangible Assets [Line Items]      
Gross Intangible 3,876 3,628  
Accumulated Amortization 2,639 2,431  
Net Intangible $ 1,237 1,197  
Weighted- Average Remaining Amortization Period (Years) 11 years    
Trademarks, trade names, and patents      
Finite-Lived Intangible Assets [Line Items]      
Gross Intangible $ 1,340 561  
Accumulated Amortization 459 408  
Net Intangible $ 881 153  
Weighted- Average Remaining Amortization Period (Years) 8 years    
Developed technology and other      
Finite-Lived Intangible Assets [Line Items]      
Gross Intangible $ 1,030 1,047  
Accumulated Amortization 726 684  
Net Intangible $ 304 $ 363  
Weighted- Average Remaining Amortization Period (Years) 6 years    
Noncompete Agreements      
Finite-Lived Intangible Assets [Line Items]      
Gross Intangible $ 72    
Accumulated Amortization 21    
Net Intangible $ 51    
Weighted- Average Remaining Amortization Period (Years) 4 years    
v3.25.2
Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($)
 3 Months Ended 12 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Goodwill [Line Items]          
Goodwill $ 4,725,000,000   $ 9,691,000,000 $ 4,725,000,000 $ 4,613,000,000
Goodwill impairment loss       675,000,000  
Amortization of Intangible Assets     303,000,000 264,000,000 281,000,000
Estimated annual amortization of intangible assets - 2026     360,000,000    
Estimated annual amortization of intangible assets - 2027     364,000,000    
Estimated annual amortization of intangible assets - 2028     330,000,000    
Estimated annual amortization of intangible assets - 2029     307,000,000    
Estimated annual amortization of intangible assets - 2030     284,000,000    
GMPD          
Goodwill [Line Items]          
Goodwill 0   0 0 681,000,000
Accumulated goodwill impairment loss 5,400,000,000     5,400,000,000  
Goodwill impairment loss 90,000,000 $ 585,000,000   675,000,000 1,200,000,000
Other Operating Segment          
Goodwill [Line Items]          
Goodwill 1,170,000,000   1,748,000,000 1,170,000,000 1,170,000,000
Accumulated goodwill impairment loss 829,000,000   829,000,000 829,000,000  
Goodwill impairment loss       0  
Pharmaceutical and Specialty Solutions          
Goodwill [Line Items]          
Goodwill 3,555,000,000   $ 7,943,000,000 3,555,000,000 $ 2,762,000,000
Goodwill impairment loss       0  
Pharmaceutical and Specialty Solutions | Outcomes Divestiture          
Goodwill [Line Items]          
Disposal Group, Including Discontinued Operation, Goodwill $ 24,000,000     $ 24,000,000  
v3.25.2
Leases (Details)
Jun. 30, 2025
Jun. 30, 2024
Operating Lease, Weighted Average Remaining Lease Term 5 years 10 months 24 days 5 years 6 months
Operating Lease, Weighted Average Discount Rate, Percent 3.90% 4.10%
Finance Lease, Weighted Average Remaining Lease Term 6 years 3 months 18 days 4 years 1 month 6 days
Finance Lease, Weighted Average Discount Rate, Percent 4.60% 4.40%
v3.25.2
Leases Schedule of Lease Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Leases [Abstract]      
Operating Lease, Cost $ 157 $ 120 $ 112
Amortization of right-of-use assets 51 39 31
Variable lease cost 43 31 21
Total lease cost $ 251 $ 190 $ 164
v3.25.2
Leases Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Leases [Abstract]    
Operating Lease, Liability, Noncurrent $ 654 $ 400
Operating Lease, Right-of-Use Asset 758 475
Operating Lease, Liability, Current 164 117
Total operating lease liabilities 818 517
Total finance lease liabilities 201 108
Finance Lease, Right-of-Use Asset, after Accumulated Amortization 192 102
Finance Lease, Liability, Current 44 33
Finance Lease, Liability, Noncurrent $ 157 $ 75
Operating Lease, Weighted Average Remaining Lease Term 5 years 10 months 24 days 5 years 6 months
Finance Lease, Weighted Average Remaining Lease Term 6 years 3 months 18 days 4 years 1 month 6 days
Operating Lease, Weighted Average Discount Rate, Percent 3.90% 4.10%
Finance Lease, Weighted Average Discount Rate, Percent 4.60% 4.40%
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other assets Other assets
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other accrued liabilities Other accrued liabilities
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Deferred income taxes and other liabilities Deferred income taxes and other liabilities
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Property and equipment, net Property and equipment, net
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Current portion of long-term obligations and other short-term borrowings Current portion of long-term obligations and other short-term borrowings
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Long-term obligations, less current portion Long-term obligations, less current portion
v3.25.2
Leases Supplemental Cash Flow Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Leases [Abstract]      
Operating Lease, Payments $ 167 $ 124 $ 119
Finance Lease, Principal Payments 53 36 31
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 130 143 75
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability $ 107 $ 55 $ 42
v3.25.2
Leases Schedule of Future Lease Payments (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
2023 $ 249  
2024 219  
2025 181  
2026 136  
2027 116  
Thereafter 256  
Total future lease payments 1,157  
Less: imputed interest 138  
Total lease liabilities 818 $ 517
Total lease liabilities 201 $ 108
Total Lease Liability 1,019  
Operating Leases    
2023 197  
2024 174  
2025 146  
2026 111  
2027 97  
Thereafter 199  
Total future lease payments 924  
Less: imputed interest 106  
Total lease liabilities 818  
Finance Leases    
2023 52  
2024 45  
2025 35  
2026 25  
2027 19  
Thereafter 57  
Total future lease payments 233  
Less: imputed interest 32  
Total lease liabilities $ 201  
v3.25.2
Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Debt Instrument [Line Items]    
Other obligations $ 213 $ 110
Total 8,527 5,092
Less: current portion of long-term obligations and other short-term borrowings 550 434
Long-term obligations, less current portion 7,977 4,658
3.75% Notes due 2025    
Debt Instrument [Line Items]    
Notes Payable 501 507
3.41% Notes due fiscal 2027    
Debt Instrument [Line Items]    
Notes Payable 1,206 1,191
5.125% Notes due 2029    
Debt Instrument [Line Items]    
Notes Payable 645 644
5.45% Notes due 2034    
Debt Instrument [Line Items]    
Notes Payable 501 491
4.6% Notes due 2043    
Debt Instrument [Line Items]    
Notes Payable 323 308
4.5% Notes due 2044    
Debt Instrument [Line Items]    
Notes Payable 338 330
4.9% Notes due 2045    
Debt Instrument [Line Items]    
Notes Payable 438 423
4.368% Notes due fiscal 2047    
Debt Instrument [Line Items]    
Notes Payable 566 563
7.0% Debentures due 2026    
Debt Instrument [Line Items]    
Notes Payable $ 124 $ 124
v3.25.2
Long-Term Obligations and Other Short-Term Borrowings Narrative (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Line of Credit Facility [Line Items]    
Other Borrowings $ 213 $ 110
Maturities of existing long-term obligations and other short-term borrowings-2025 553  
Maturities of existing long-term obligations and other short-term borrowings-2026 1,900  
Maturities of existing long-term obligations and other short-term borrowings-2027 834  
Maturities of existing long-term obligations and other short-term borrowings-2028 670  
Maturities of existing long-term obligations and other short-term borrowings-2029 764  
Maturities of existing long-term obligations and other short-term borrowings-Thereafter 3,900  
3.5% Notes due 2024    
Line of Credit Facility [Line Items]    
Notes Payable 0 401
3.75% Notes due 2025    
Line of Credit Facility [Line Items]    
Notes Payable 501 507
4.7% Notes due 2026    
Line of Credit Facility [Line Items]    
Notes Payable 498 0
3.41% Notes due fiscal 2027    
Line of Credit Facility [Line Items]    
Notes Payable 1,206 1,191
5.125% Notes due 2029    
Line of Credit Facility [Line Items]    
Notes Payable 645 644
5.0% Notes due 2029    
Line of Credit Facility [Line Items]    
Notes Payable 745 0
5.45% Notes due 2034    
Line of Credit Facility [Line Items]    
Notes Payable 501 491
5.35% Notes due 2034    
Line of Credit Facility [Line Items]    
Notes Payable 989 0
4.6% Notes due 2043    
Line of Credit Facility [Line Items]    
Notes Payable 323 308
4.5% Notes due 2044    
Line of Credit Facility [Line Items]    
Notes Payable 338 330
4.9% Notes due 2045    
Line of Credit Facility [Line Items]    
Notes Payable 438 423
4.368% Notes due fiscal 2047    
Line of Credit Facility [Line Items]    
Notes Payable 566 563
5.75% Notes due 2054    
Line of Credit Facility [Line Items]    
Notes Payable 641 0
7.0% Debentures due 2026    
Line of Credit Facility [Line Items]    
Notes Payable 124 124
Floating Rate Term Loan due fiscal 2028    
Line of Credit Facility [Line Items]    
Notes Payable $ 799 $ 0
v3.25.2
Long-Term Obligations and Other Short-Term Borrowings Long-Term Debt (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Debt Instrument [Line Items]        
Accounts Payable $ 34,700 $ 34,700 $ 31,800  
Debt Instrument, Issued, Principal   2,900 1,150  
Proceeds from Issuance of Long-Term Debt   $ 2,900 1,140  
Offer as percentage of principal amount   101.00%    
Proceeds from short-term investment in time deposit   $ 200 350 $ 0
4.7% Notes due 2026        
Debt Instrument [Line Items]        
Debt Instrument, Issued, Principal   500    
5.0% Notes due 2029        
Debt Instrument [Line Items]        
Debt Instrument, Issued, Principal   750    
5.35% Notes due 2034        
Debt Instrument [Line Items]        
Debt Instrument, Issued, Principal   1,000    
5.75% Notes due 2054        
Debt Instrument [Line Items]        
Debt Instrument, Issued, Principal   650    
3.5% Notes due 2024        
Debt Instrument [Line Items]        
Repayments of Debt $ 400      
3.079% Notes due fiscal 2024        
Debt Instrument [Line Items]        
Notes Payable Repurchased   $ 750    
5.125% Notes due 2029        
Debt Instrument [Line Items]        
Debt Instrument, Issued, Principal     650  
5.45% Notes due 2034        
Debt Instrument [Line Items]        
Debt Instrument, Issued, Principal     $ 500  
v3.25.2
Long-Term Obligations and Other Short-Term Borrowings Other Financing Arrangements (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 04, 2025
Jun. 30, 2025
Apr. 01, 2025
Nov. 11, 2024
Jun. 30, 2024
Debt Instrument [Line Items]          
Other obligations   $ 213     $ 110
Revolving Credit Facility          
Debt Instrument [Line Items]          
Maximum borrowing capacity   2,000      
Short Term Credit Facilities | Committed Receivables Sales Facility Program          
Debt Instrument [Line Items]          
Maximum borrowing capacity   1,000      
Letter of Credit          
Debt Instrument [Line Items]          
Line of credit   1     1
Other Short-term Borrowings   0     0
Long-term Line of Credit   1     1
Letter of Credit | Committed Receivables Sales Facility Program          
Debt Instrument [Line Items]          
Line of credit   31     31
Long-term Line of Credit   31     31
Committed Receivables Sales Facility Program          
Debt Instrument [Line Items]          
Other Short-term Borrowings   0      
Line of Credit Facility, Maximum Amount Outstanding During Period   633      
Commercial Paper          
Debt Instrument [Line Items]          
Maximum borrowing capacity   3,000      
Other Short-term Borrowings   0     $ 0
Bridge Loan          
Debt Instrument [Line Items]          
Maximum borrowing capacity       $ 2,900  
364-Dad Revolving Credit Facility | Backstop Credit Facility          
Debt Instrument [Line Items]          
Maximum borrowing capacity   1,000      
364-Dad Revolving Credit Facility | Backstop Credit Facility | Forecast          
Debt Instrument [Line Items]          
Debt Instrument, Term 364 days        
Credit Agreement          
Debt Instrument [Line Items]          
Maximum borrowing capacity   $ 1,000      
Line of credit     $ 800    
Long-term Line of Credit     $ 800    
v3.25.2
Commitments, Contingent Liabilities and Litigation (Details)
 3 Months Ended 5 Months Ended 12 Months Ended 49 Months Ended 155 Months Ended
Apr. 30, 2023
USD ($)
lawsuit
Jul. 31, 2014
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2025
USD ($)
numberOfUSTerritories
states
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
states
Jul. 31, 2025
USD ($)
Jun. 30, 2038
USD ($)
Aug. 08, 2025
lawsuit
Aug. 31, 2024
USD ($)
Nov. 30, 2023
USD ($)
Oct. 31, 2022
USD ($)
Jul. 31, 2022
USD ($)
Apr. 30, 2018
USD ($)
Loss Contingencies [Line Items]                              
Gain (Loss) Related to Litigation Settlement         $ 185,000,000 $ (78,000,000) $ 304,000,000                
Income from Settlements of Class Action Lawsuits         $ 171,000,000 117,000,000 $ 130,000,000                
CVS Health Corporation                              
Loss Contingencies [Line Items]                              
Long-Term Purchase Commitment, Period   10 years                          
Opioid Lawsuits                              
Loss Contingencies [Line Items]                              
Loss Contingency, Number of State | states         50   48                
Settling U.S Territories | numberOfUSTerritories         5                    
Payments for Legal Settlements         $ 798,000,000                    
Insurance Recoveries         25,000,000 34,000,000                  
Insurance Recoveries - Pharma         12,000,000                    
Opioid Lawsuits | Subsequent Event                              
Loss Contingencies [Line Items]                              
Payments for Legal Settlements               $ 2,200,000,000 $ 4,100,000,000            
Product Liability Lawsuits                              
Loss Contingencies [Line Items]                              
Loss Contingency Accrual, Period Increase (Decrease)           103,000,000                  
Product Liability Lawsuits | IVC April 2023 Agreement                              
Loss Contingencies [Line Items]                              
Payments for Legal Settlements     $ 49,000,000 $ 275,000,000                      
Loss Contingency, Estimate of Possible Loss $ 275,000,000                            
New York Opioid Stewardship Act                              
Loss Contingencies [Line Items]                              
Aggregate Annual Assessment                             $ 100,000,000
WEST VIRGINIA | Opioid Lawsuits                              
Loss Contingencies [Line Items]                              
Loss Contingency, Estimate of Possible Loss                           $ 124,000,000  
921150 American Indian and Alaska Native Tribal Governments | Opioid Lawsuits                              
Loss Contingencies [Line Items]                              
Loss Contingency, Estimate of Possible Loss                         $ 136,000,000    
ALABAMA | Opioid Lawsuits                              
Loss Contingencies [Line Items]                              
Loss Contingency, Estimate of Possible Loss                       $ 123,000,000      
Litigation Settlement, Loss           22,000,000                  
City of Baltimore | Opioid Lawsuits                              
Loss Contingencies [Line Items]                              
Loss Contingency, Estimate of Possible Loss                     $ 153,000,000        
Total Opioid Litigation [Member]                              
Loss Contingencies [Line Items]                              
Loss Contingency Accrual, Period Increase (Decrease)           344,000,000                  
Estimated Litigation Liability         4,900,000,000                    
Estimated Litigation Liability, Current         628,000,000                    
Litigation settlement             $ 5,600,000,000                
Litigation Settlement, Loss           340                  
Income As A Result Of Prepayments           $ 105,000,000                  
Private Parties [Member] | Opioid Lawsuits | Subsequent Event                              
Loss Contingencies [Line Items]                              
Loss Contingency, Lawsuits, Number | lawsuit                   291          
Class Action Lawsuits [Member] | Private Parties [Member] | Opioid Lawsuits                              
Loss Contingencies [Line Items]                              
Estimated Litigation Liability         213,000,000                    
Class Action Lawsuits [Member] | Private Parties [Member] | Opioid Lawsuits | Subsequent Event                              
Loss Contingencies [Line Items]                              
Loss Contingency, Lawsuits, Number | lawsuit                   11          
Product Liability Lawsuits | IVC April 2023 Agreement                              
Loss Contingencies [Line Items]                              
Loss Contingency, Claims Settled, Number | lawsuit 4,375                            
Product Liability Lawsuits | Minimum                              
Loss Contingencies [Line Items]                              
Loss contingency accrual         $ 56,000,000                    
v3.25.2
Income Taxes (Schedule of Income before Income Tax, Domestic and Foreign) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Income Tax Disclosure [Abstract]      
U.S. operations $ 1,715 $ 892 $ 316
Non-U.S. operations 386 309 347
Earnings before income taxes $ 2,101 $ 1,201 $ 663
v3.25.2
Income Taxes (Schedule of Components of Income Tax Expense (Benefit), Current and Deferred) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Current:      
Federal $ 135 $ 305 $ 219
State and local 72 68 69
Non-U.S. 82 79 84
Total current 289 452 372
Deferred:      
Federal 205 (89) (23)
State and local 39 12 11
Non-U.S. (1) (27) (28)
Total deferred 243 (104) (40)
Provision for income taxes $ 532 $ 348 $ 332
v3.25.2
Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Income Tax Disclosure [Abstract]      
Provision at Federal statutory rate 21.00% 21.00% 21.00%
State and local income taxes, net of federal benefit 4.00% 3.10% 6.50%
Tax effect of foreign operations 0.20% (1.60%) (5.40%)
Nondeductible/nontaxable items 0.70% (0.10%) (1.10%)
Impact of Divestitures 0.00% 0.00% (1.90%)
Withholding Taxes 0.30% 1.00% 1.00%
Change in Valuation Allowances 0.10% (1.10%) (5.10%)
US Taxes on International Income (1) (1.30%) (2.10%) 0.60%
Impact of Resolutions with IRS and other related matters (0.10%) 0.40% 0.30%
Opioid litigation 0.20% 1.00% 0.10%
Goodwill Impairment 0.00% 8.70% 33.80%
Effective Tax Rate Reconcillation Specialty Alliance Share-based Compensation 1.40% 0.00% 0.00%
Other (1.20%) (1.40%) 0.20%
Effective income tax rate 25.30% 28.90% 50.00%
v3.25.2
Income Taxes (Narrative) (Details) - USD ($)
 3 Months Ended 12 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Income Taxes            
Goodwill impairment loss       $ 675,000,000    
Income Tax Expense (Benefit)     $ 532,000,000 $ 348,000,000 $ 332,000,000  
Effective Income Tax Rate Reconciliation, Percent     25.30% 28.90% 50.00%  
Provision at Federal statutory rate     21.00% 21.00% 21.00%  
Deferred income taxes and other liabilities $ 8,035,000,000   $ 8,882,000,000 $ 8,035,000,000    
Unrecognized tax benefits that would impact effective tax rate 882,000,000   871,000,000 882,000,000 $ 878,000,000  
Effective Tax Rate Impact From Certain Foreign Jurisdictions     17,000,000      
Undistributed Earnings of Foreign Subsidiaries     1,000,000,000.0      
Deferred tax assets on tax credit carryforwards (512,000,000)   (386,000,000) (512,000,000)    
Valuation allowance on operating loss carryforwards     244,000,000      
Unrecognized tax benefits 981,000,000   879,000,000 981,000,000 1,015,000,000 $ 948,000,000
Unrecognized tax benefits, interest and penalties accrued 65,000,000   65,000,000 65,000,000 65,000,000  
GMPD            
Income Taxes            
Goodwill impairment loss $ 90,000,000 $ 585,000,000   675,000,000 1,200,000,000  
Federal            
Income Taxes            
Tax credit carryforwards     154,000,000      
State and Local            
Income Taxes            
Tax credit carryforwards     11,600,000,000      
Foreign            
Income Taxes            
Tax credit carryforwards     $ 1,100,000,000      
Total Opioid Litigation [Member]            
Income Taxes            
Litigation settlement         5,600,000,000  
GMPD            
Income Taxes            
Income Tax Expense (Benefit)       $ (58,000,000) $ (92,000,000)  
v3.25.2
Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Deferred income tax assets:    
Receivable basis difference $ 26 $ 81
Accrued liabilities 651 749
Share-based compensation 23 28
Loss and tax credit carryforwards 386 512
Deferred tax assets related to uncertain tax positions 47 45
Other 97 76
Total deferred income tax assets 1,230 1,491
Valuation allowance for deferred income tax assets (254) (300)
Net deferred income tax assets 976 1,191
Deferred income tax liabilities:    
Inventory basis differences (1,103) (1,122)
Property-related (358) (350)
Other (834) (710)
Deferred Tax Liabilities, Deferred Expense, Reserves and Accruals (981) (981)
Total deferred income tax liabilities (3,276) (3,163)
Net deferred income tax liability $ (2,300) $ (1,972)
v3.25.2
Income Taxes (Schedule of Deferred Tax Assets and Liabilities After Netting by Tax Jurisdiction) (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Income Tax Disclosure [Abstract]    
Noncurrent deferred income tax asset $ 64 $ 72
Noncurrent deferred income tax liability (2,364) (2,044)
Net deferred income tax liability $ (2,300) $ (1,972)
v3.25.2
Income Taxes (Schedule of Unrecognized Tax Benefits Roll Forward) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Income Tax Disclosure [Abstract]      
Current Federal Tax Expense (Benefit) $ 135 $ 305 $ 219
Current State and Local Tax Expense (Benefit) 72 68 69
Current Foreign Tax Expense (Benefit) 82 79 84
Current Income Tax Expense (Benefit) 289 452 372
Deferred Federal Income Tax Expense (Benefit) 205 (89) (23)
Deferred State and Local Income Tax Expense (Benefit) 39 12 11
Deferred Foreign Income Tax Expense (Benefit) (1) (27) (28)
Deferred Income Tax Expense (Benefit) 243 (104) (40)
Income Tax Expense (Benefit) 532 348 332
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Balance at beginning of fiscal year 981 1,015 948
Additions for tax positions of the current year 8 30 25
Additions for tax positions of prior years 15 28 133
Reductions for tax positions of prior years (101) (87) (16)
Settlements with tax authorities (22) (3) (73)
Expiration of the statute of limitations (2) (2) (2)
Balance at end of fiscal year $ 879 $ 981 $ 1,015
v3.25.2
Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Jul. 10, 2023
Transaction Data System Investment      
Assets:      
Equity ownership percentage 16.00%    
Fair Value, Measurements, Recurring      
Assets:      
Cash equivalents $ 1,672 $ 1,442  
Forward contracts (48) (87)  
Equity Securities, FV-NI (843)    
Other investments 108 108  
Fair Value, Measurements, Recurring | Level 1      
Assets:      
Cash equivalents 1,672 1,442  
Forward contracts 0 0  
Equity Securities, FV-NI 0    
Other investments 108 108  
Fair Value, Measurements, Recurring | Level 2      
Assets:      
Cash equivalents 0 0  
Forward contracts (48) (87)  
Equity Securities, FV-NI 0    
Other investments 0 0  
Fair Value, Measurements, Recurring | Level 3      
Assets:      
Cash equivalents 0 0  
Forward contracts 0 0  
Equity Securities, FV-NI (843)    
Other investments $ 0 $ 0  
Fair Value, Nonrecurring | Level 3 | Transaction Data System Investment      
Assets:      
Equity Method Investments, Fair Value Disclosure     $ 147
v3.25.2
Financial Instruments (Schedule of the Fair Value of Assets and Liabilities Related to Derivatives Designated as Hedging Instruments) (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Derivatives, Fair Value [Line Items]    
Total assets $ 20 $ 16
Total liabilities 68 103
Designated as Hedging Instrument | Cash Flow Hedging | Foreign Currency Contracts | Prepaid Expenses and Other    
Derivatives, Fair Value [Line Items]    
Total assets 6 1
Designated as Hedging Instrument | Cash Flow Hedging | Foreign Currency Contracts | Other Accrued Liabilities    
Derivatives, Fair Value [Line Items]    
Total liabilities 1 8
Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap | Other Accrued Liabilities    
Derivatives, Fair Value [Line Items]    
Total liabilities 43 94
Designated as Hedging Instrument | Fair Value Hedging | Cross Currency Interest Rate Contract [Member] | Prepaid Expenses and Other    
Derivatives, Fair Value [Line Items]    
Total assets 0 12
Designated as Hedging Instrument | Fair Value Hedging | Cross Currency Interest Rate Contract [Member] | Other Accrued Liabilities    
Derivatives, Fair Value [Line Items]    
Total liabilities $ 24 $ 1
v3.25.2
Financial Instruments (Narrative) (Details)
€ in Millions, ¥ in Millions, $ in Millions
 3 Months Ended 12 Months Ended
Jun. 30, 2024
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2025
EUR (€)
Jun. 30, 2025
JPY (¥)
Jun. 30, 2024
EUR (€)
Jun. 30, 2024
JPY (¥)
Derivative [Line Items]                  
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments     $ 0 $ 0 $ 0        
Proceeds from net investment hedge terminations     2 34 $ 29        
September 2018                  
Derivative [Line Items]                  
Proceeds from net investment hedge terminations $ 19                
March 2022                  
Derivative [Line Items]                  
Proceeds from net investment hedge terminations 10                
January 2023                  
Derivative [Line Items]                  
Proceeds from net investment hedge terminations     28            
June 2027 [Member]                  
Derivative [Line Items]                  
Proceeds from net investment hedge terminations     6            
March 2025 [Member]                  
Derivative [Line Items]                  
Proceeds from Hedge, Financing Activities     2            
Foreign Currency Contracts                  
Derivative [Line Items]                  
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax     33 (26)          
Interest Income (Expense), Nonoperating, Net     9 14          
Fair Value Hedging | Interest Rate Swap                  
Derivative [Line Items]                  
Derivative, notional amount     1,600            
Notional Amount 1,600   1,600 1,600          
Cash Flow Hedging | Currency Swap [Member]                  
Derivative [Line Items]                  
Notional Amount 334   332 334          
Cash Flow Hedging | Foreign Currency Contracts                  
Derivative [Line Items]                  
Derivative, notional amount 401   381 401          
Notional Amount 579   575 579          
Cash Flow Hedging | Foreign Currency Contracts | Forecast | Subsequent Event                  
Derivative [Line Items]                  
Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months   $ 5              
Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap                  
Derivative [Line Items]                  
Derivative Liability, Notional Amount 300   500 300          
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | September 2018                  
Derivative [Line Items]                  
Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount 233     233       € 200  
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | March 2022                  
Derivative [Line Items]                  
Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount 400     400         ¥ 48,000
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | January 2023                  
Derivative [Line Items]                  
Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount     300       ¥ 38,000    
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | June 2027 [Member]                  
Derivative [Line Items]                  
Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount     120       18,000    
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | September 2025 [Member]                  
Derivative [Line Items]                  
Derivative Liability, Notional Amount 150     150         19,000
Notional Amount     120       18,000    
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | March 2026 [Member]                  
Derivative [Line Items]                  
Derivative Liability, Notional Amount 107     107       100  
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | March 2025 [Member]                  
Derivative [Line Items]                  
Derivative Liability, Notional Amount 107     107       € 100  
Notional Amount     107     € 100      
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | June 2027 [Member]                  
Derivative [Line Items]                  
Derivative Liability, Notional Amount $ 150     $ 150         ¥ 19,000
Notional Amount     120       ¥ 18,000    
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | February 2027                  
Derivative [Line Items]                  
Notional Amount     $ 105     € 100      
v3.25.2
Financial Instruments (Schedule of Outstanding Instruments, Fair Value Hedges) (Details)
$ in Millions
Jun. 30, 2025
USD ($)
Fair Value Hedging | Interest Rate Swap  
Derivative [Line Items]  
Notional Amount $ 1,600
v3.25.2
Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Interest Rate Contracts Designated as Fair Value Hedges) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Derivative [Line Items]      
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Interest expense, net Interest expense, net Interest expense, net
Fair Value Hedging | Interest Rate Swap      
Derivative [Line Items]      
Gain/(loss) on derivative $ 51 $ 2 $ (50)
Fair Value Hedging | Fixed-Rate Debt      
Derivative [Line Items]      
Gain/(loss) on derivative $ (51) $ (2) $ 50
v3.25.2
Financial Instruments (Schedule of Outstanding Instruments, Cash Flow Hedges) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
SG&A Expenses      
Derivative [Line Items]      
OCI, Cash Flow Hedge, Reclassification for Discontinuance, Statement of Income or Comprehensive Income [Extensible Enumeration] Distribution, selling, general, and administrative expenses Distribution, selling, general, and administrative expenses Distribution, selling, general, and administrative expenses
Fair Value Hedging | Interest Rate Swap      
Derivative [Line Items]      
Notional Amount $ 1,600    
Cash Flow Hedging | Foreign Currency Contracts      
Derivative [Line Items]      
Notional Amount 381 $ 401  
Cash Flow Hedging | Foreign Currency Contracts | SG&A Expenses      
Derivative [Line Items]      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (1) 0 $ 1
Cash Flow Hedging | Forward Contracts [Member]      
Derivative [Line Items]      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 2 2 $ 2
Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap      
Derivative [Line Items]      
Derivative Liability, Notional Amount $ 500 $ 300  
v3.25.2
Financial Instruments (Schedule of Gain/(Loss) Included in AOCI for Derivative Instruments Designated as Cash Flow Hedges) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Cash Flow Hedging | Foreign Currency Contracts      
Derivative [Line Items]      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax $ 11 $ (7) $ (2)
v3.25.2
Financial Instruments (Schedule of Gain/(Loss) Reclassified from AOCI into Earnings for Derivative Instruments Designated as Cash Flow Hedges) (Details) - Cash Flow Hedging - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Foreign Currency Contracts | Revenue      
Derivative [Line Items]      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax $ 3 $ 1 $ 9
Foreign Currency Contracts | Cost of Products Sold      
Derivative [Line Items]      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (6) 4 2
Foreign Currency Contracts | SG&A Expenses      
Derivative [Line Items]      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (1) 0 1
Forward Contracts [Member]      
Derivative [Line Items]      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax $ 2 $ 2 $ 2
v3.25.2
Financial Instruments (Schedule of Outstanding Instruments, Economic Hedges) (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Foreign Currency Contracts | Not Designated as Hedging Instrument    
Derivative [Line Items]    
Notional Amount $ 194 $ 178
v3.25.2
Financial Instruments (Schedule of Gain/(Loss) Recognized in Earnings for Derivatives Not Designated as Hedging Instrument) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Not Designated as Hedging Instrument | Foreign Currency Contracts | Other Income, Net      
Derivative [Line Items]      
Gain/(loss) recognized in earnings for economic (non-designated) derivative instruments $ (6) $ 1 $ (7)
v3.25.2
Financial Instruments (Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings) (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Carrying Amount of Long-Term and other Short-Term Borrowings $ 8,527 $ 5,092
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Estimated fair value $ 8,388 $ 4,891
v3.25.2
Financial Instruments (Schedule of Fair Value Gain Loss Derivative Instrument) (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Fair Value Hedging | Interest Rate Swap    
Derivative [Line Items]    
Notional Amount $ 1,600 $ 1,600
Fair Value Gain/(Loss) (29) (91)
Cash Flow Hedging | Foreign Currency Contracts    
Derivative [Line Items]    
Notional Amount 575 579
Fair Value Gain/(Loss) 5 (7)
Cash Flow Hedging | Currency Swap [Member]    
Derivative [Line Items]    
Notional Amount 332 334
Fair Value Gain/(Loss) $ (24) $ 11
v3.25.2
Shareholders' Equity (Narrative) (Details)
$ / shares in Units, $ in Millions
 2 Months Ended 3 Months Ended 4 Months Ended 12 Months Ended 36 Months Ended
Mar. 11, 2025
$ / shares
Mar. 31, 2025
shares
Dec. 31, 2024
shares
Sep. 30, 2023
shares
Oct. 30, 2024
$ / shares
Jun. 30, 2025
USD ($)
shares
Jun. 30, 2024
USD ($)
$ / shares
shares
Jun. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2023
USD ($)
Class of Stock [Line Items]                  
Treasury Stock, Value, Acquired, Cost Method | $           $ 757 $ 759 $ 2,007  
Share repurchase program activity | $           $ 765 $ 750 2,000  
Common shares, authorized           755,000,000 755,000,000    
Treasury Stock, Shares, Retired           0      
Preferred shares, authorized           500,000 500,000    
Share Repurchase Programs                  
Class of Stock [Line Items]                  
Share Repurchase Program, Excise Tax | $           $ 15      
Common Class A                  
Class of Stock [Line Items]                  
Common shares, authorized           750,000,000 750,000,000    
Common Stock, Voting Rights, Votes           1      
Common Class B                  
Class of Stock [Line Items]                  
Common shares, authorized           5,000,000 5,000,000    
Treasury Shares                  
Class of Stock [Line Items]                  
Treasury Stock, Value, Acquired, Cost Method | $           $ 757 $ 859 $ 1,907  
Treasury Stock, Shares, Acquired           6,400,000 9,000,000.0 24,600,000  
Share repurchase program activity | $                 $ 3,500
Treasury Stock, Shares, Retired           56,000,000      
Treasury Shares | $375 million share repurchase program                  
Class of Stock [Line Items]                  
Treasury Stock, Shares, Acquired   3,000,000 3,400,000            
Treasury shares acquired, average price per share (in usd per share) | $ / shares $ 125.87       $ 110.10        
Treasury Shares | $500 million share repurchase program [Member]                  
Class of Stock [Line Items]                  
Treasury Stock, Shares, Acquired       900,000       4,600,000  
Treasury shares acquired, average price per share (in usd per share) | $ / shares             $ 91.15 $ 87.18  
Treasury Shares | $250 million share repurchase program                  
Class of Stock [Line Items]                  
Treasury Stock, Shares, Acquired             5,700,000 3,200,000  
Treasury shares acquired, average price per share (in usd per share) | $ / shares             $ 88.22 $ 77.50  
Treasury Shares | Second $250 million share repurchase program [Member]                  
Class of Stock [Line Items]                  
Treasury Stock, Shares, Acquired               3,200,000  
Treasury shares acquired, average price per share (in usd per share) | $ / shares               $ 77.27  
Treasury Shares | $1 billion share repurchase program                  
Class of Stock [Line Items]                  
Treasury Stock, Shares, Acquired             2,400,000 13,600,000  
Treasury shares acquired, average price per share (in usd per share) | $ / shares             $ 103.67 $ 73.36  
v3.25.2
Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period $ (3,212) $ (2,957) $ (882)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 (16) (37)
Balance at end of period (2,634) (3,212) (2,957)
Other Comprehensive Income (Loss), Tax (6) 5  
Foreign Currency Translation Adjustments and Other      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period (138) (137)  
Other comprehensive loss, before reclassifications (3) (1)  
Amounts reclassified to earnings 0 0  
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (3) (1)  
Balance at end of period (141) (138) (137)
Accumulated Gain (Loss), Net, Cash Flow Hedge, Noncontrolling Interest      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period (29) (14)  
Other comprehensive loss, before reclassifications 13 (7)  
Amounts reclassified to earnings 2 (8)  
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 15 (15)  
Balance at end of period (14) (29) (14)
AOCI Including Portion Attributable to Noncontrolling Interest [Member]      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at end of period (155)    
Accumulated Other Comprehensive Loss      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of period (167) (151) (114)
Other comprehensive loss, before reclassifications 10 (8)  
Amounts reclassified to earnings 2 (8)  
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 (16) (37)
Balance at end of period $ (155) $ (167) $ (151)
v3.25.2
Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Earnings Per Share [Abstract]      
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $ 1,569 $ 853 $ 331
Net earnings attributable to noncontrolling interest (8) (1) (1)
Net Income (Loss) $ 1,561 $ 852 $ 330
Weighted-average common shares–basic (in shares) 241 245 261
Effect of dilutive securities:      
Employee stock options, restricted share units, and performance share units (in shares) 1 2 1
Weighted-average common shares–diluted (in shares) 242 247 262
Diluted earnings per common share attributable to Cardinal Health, Inc.:      
Basic (in dollars per share) $ 6.48 $ 3.48 $ 1.27
Diluted (in dollars per share) $ 6.45 $ 3.45 $ 1.26
v3.25.2
Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) - shares
shares in Millions
 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Earnings Per Share [Abstract]    
Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares) 1 2
v3.25.2
Segment Information (Narrative) (Details)
$ in Millions
 12 Months Ended
Jun. 30, 2025
USD ($)
segment
Segments
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Segment Reporting Information [Line Items]      
Number of Reportable Segments | segment 2    
Project costs on investment and other spending | $ $ 72 $ 59 $ 35
Other Operating Segment      
Segment Reporting Information [Line Items]      
Number of Operating Segments | Segments 3    
v3.25.2
Segment Information (Revenue by Reportable Segment) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Segment Reporting Information [Line Items]      
Revenue $ 222,578 $ 226,827 $ 204,979
Cost of products sold 214,410 219,413 198,105
Distribution, selling, general, and administrative expenses 5,382 5,000 4,800
Depreciation and amortization 790 710 692
Non-US [Member]      
Segment Reporting Information [Line Items]      
Revenue 1,669 1,681 1,617
United States      
Segment Reporting Information [Line Items]      
Revenue 220,993 225,231 203,440
Operating Segments      
Segment Reporting Information [Line Items]      
Revenue 222,662 226,912 205,057
Cost of products sold 214,492 219,495 198,181
Distribution, selling, general, and administrative expenses 5,261 4,887 4,746
Costs and Expenses 219,753 224,382 202,927
Operating Segments | GMPD      
Segment Reporting Information [Line Items]      
Revenue 12,636 12,381 12,222
Cost of products sold 10,470 10,264 10,377
Distribution, selling, general, and administrative expenses 2,031 2,025 1,992
Costs and Expenses 12,501 12,289 12,369
Depreciation and amortization 212 205 173
Operating Segments | Other Operating Segment      
Segment Reporting Information [Line Items]      
Revenue 5,382 4,512 4,021
Cost of products sold 4,023 3,367 2,990
Distribution, selling, general, and administrative expenses 843 722 635
Costs and Expenses 4,866 4,089 3,625
Depreciation and amortization 88 79 71
Operating Segments | Other Operating Segment | OptiFreight Logistics      
Segment Reporting Information [Line Items]      
Revenue 324 274 240
Operating Segments | Other Operating Segment | at-Home Solutions      
Segment Reporting Information [Line Items]      
Revenue 3,480 2,869 2,584
Operating Segments | Other Operating Segment | Nuclear Precision Health Solutions      
Segment Reporting Information [Line Items]      
Revenue 1,578 1,369 1,197
Operating Segments | Pharmaceutical and Specialty Solutions      
Segment Reporting Information [Line Items]      
Revenue 204,644 210,019 188,814
Cost of products sold 199,999 205,864 184,814
Distribution, selling, general, and administrative expenses 2,387 2,140 2,119
Costs and Expenses 202,386 208,004 186,933
Depreciation and amortization 185 184 194
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]      
Segment Reporting Information [Line Items]      
Revenue (84) (85) (78)
Depreciation and amortization $ 305 $ 242 $ 254
v3.25.2
Segment Information (Segment Profit by Reportable Segment) (Details)
$ in Millions
 12 Months Ended
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Number of Reportable Segments | segment 2    
Cost of products sold $ 214,410 $ 219,413 $ 198,105
Distribution, selling, general, and administrative expenses 5,382 5,000 4,800
Operating Income (Loss) 2,275 1,243 752
Operating Segments      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Cost of products sold 214,492 219,495 198,181
Distribution, selling, general, and administrative expenses 5,261 4,887 4,746
Costs and Expenses 219,753 224,382 202,927
Operating Income (Loss) 2,909 2,530 2,130
Operating Segments | Pharmaceutical and Specialty Solutions      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Cost of products sold 199,999 205,864 184,814
Distribution, selling, general, and administrative expenses 2,387 2,140 2,119
Costs and Expenses 202,386 208,004 186,933
Operating Income (Loss) 2,258 2,015 1,881
Operating Segments | GMPD      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Cost of products sold 10,470 10,264 10,377
Distribution, selling, general, and administrative expenses 2,031 2,025 1,992
Costs and Expenses 12,501 12,289 12,369
Operating Income (Loss) 135 92 (147)
Operating Segments | Other Operating Segment      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Cost of products sold 4,023 3,367 2,990
Distribution, selling, general, and administrative expenses 843 722 635
Costs and Expenses 4,866 4,089 3,625
Operating Income (Loss) 516 423 396
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]      
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]      
Operating Income (Loss) $ (634) $ (1,287) $ (1,378)
v3.25.2
Segment Information (Depreciation and Amortization and Additions to Property and Equipment by Reportable Segment) (Details)
$ in Millions
 12 Months Ended
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Segment Reporting Information [Line Items]      
Total depreciation and amortization $ 790 $ 710 $ 692
Segment, Expenditure, Addition to Long-Lived Assets $ 547 511 481
Number of Reportable Segments | segment 2    
Operating Segments | Pharmaceutical and Specialty Solutions      
Segment Reporting Information [Line Items]      
Total depreciation and amortization $ 185 184 194
Segment, Expenditure, Addition to Long-Lived Assets 118 76 56
Operating Segments | GMPD      
Segment Reporting Information [Line Items]      
Total depreciation and amortization 212 205 173
Segment, Expenditure, Addition to Long-Lived Assets 133 136 191
Operating Segments | Other Operating Segment      
Segment Reporting Information [Line Items]      
Total depreciation and amortization 88 79 71
Segment, Expenditure, Addition to Long-Lived Assets 88 81 52
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]      
Segment Reporting Information [Line Items]      
Total depreciation and amortization 305 242 254
Segment, Expenditure, Addition to Long-Lived Assets $ 208 $ 218 $ 182
v3.25.2
Segment Information (Assets by Reportable Segment) (Details)
$ in Millions
 12 Months Ended
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Segment Reporting Information [Line Items]    
Total assets $ 53,122 $ 45,121
Number of Reportable Segments | segment 2  
Operating Segments | GMPD    
Segment Reporting Information [Line Items]    
Total assets $ 6,889 7,047
Operating Segments | Other Operating Segment    
Segment Reporting Information [Line Items]    
Total assets 4,045 2,606
Operating Segments | Pharmaceutical and Specialty Solutions    
Segment Reporting Information [Line Items]    
Total assets 37,313 29,149
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]    
Segment Reporting Information [Line Items]    
Total assets $ 4,875 $ 6,319
v3.25.2
Segment Information Property and Equipment, net by Geographic Area) (Details) - USD ($)
$ in Millions
Jun. 30, 2025
Jun. 30, 2024
Long-Lived Assets [Line Items]    
Property and equipment, net $ 2,858 $ 2,529
United States    
Long-Lived Assets [Line Items]    
Property and equipment, net 2,422 2,106
International    
Long-Lived Assets [Line Items]    
Property and equipment, net $ 436 $ 423
v3.25.2
Share-Based Compensation (Narrative) (Details)
shares in Thousands, $ in Millions
 2 Months Ended 12 Months Ended
Mar. 31, 2025
USD ($)
Jun. 30, 2025
USD ($)
grantees
shares
Jun. 30, 2024
USD ($)
shares
Jun. 30, 2023
USD ($)
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-Based Payment Arrangement, Plan Modification, Number of Grantees Affected | grantees   4    
Total share-based compensation expense   $ 121.0 $ 121.0 $ 96.0
Tax benefit related to share-based compensation   14.0 16.0 12.0
Total expense on employee retirement savings plans   89.0 65.0 66.0
Share-Based Payment Arrangement, Plan Modification, Incremental Cost   9.0    
Performance Share Units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense   50.0 44.0 32.0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount   $ 47.0 $ 46.0 $ 38.0
Weighted-average period over which stock option compensation cost is expected to be recognized   2 years 2 years 2 years
Performance Share Units | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Target performance goal (as a percent)   240.00%    
Stock Options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares) | shares   0 0 0
GIA Common Stock        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense $ 123.0 $ 41.0    
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount   $ 339.0    
Weighted-average period over which stock option compensation cost is expected to be recognized   2 years    
Share-Based Payment Arrangement, Acquisition Related Expense 120.0      
Share-Based Payment Arrangement, Non-Acquisition-Related Expense $ 3.0      
2021 LTIP [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares available for grant | shares   15,000    
2021 LTIP [Member] | Awards Other than Stock Options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares available for grant | shares   6,000    
2021 LTIP [Member] | Stock Options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares available for grant | shares   15,000    
v3.25.2
Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 5 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Jan. 30, 2025
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total share-based compensation expense   $ 121 $ 121 $ 96  
Restricted Share Unit          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total share-based compensation expense   $ 71 $ 77 $ 64  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 1,400 1,400 1,700 2,200  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $ 86.30 $ 86.30 $ 70.98 $ 57.37  
Granted (in shares)   700 900    
Granted (in usd per share)   $ 108.72 $ 91.06    
Vested (in shares)   (900) (1,200)    
Vested (in usd per share)   $ 72.07 $ 60.47    
Canceled and forfeited (in shares)   (100) (200)    
Canceled and forfeited (in usd per share)   $ 94.67 $ 74.40    
Performance Share Units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total share-based compensation expense   $ 50 $ 44 $ 32  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 1,500 1,500 1,300 1,200  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $ 99.45 $ 99.45 $ 97.03 $ 82.17  
Granted (in shares)   500 500    
Granted (in usd per share)   $ 113.88 $ 94.66    
Vested (in shares)   (300) (400)    
Vested (in usd per share)   $ 108.79 $ 62.26    
Canceled and forfeited (in shares)   0 0    
Canceled and forfeited (in usd per share)   $ 0 $ 0    
GIA Units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 220,000 220,000     216,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $ 1.54 $ 1.54     $ 1.46
Granted (in shares) 61,000        
Granted (in usd per share) $ 1.46        
Vested (in shares) (56,000)        
Vested (in usd per share) $ 1.46        
Canceled and forfeited (in shares) (1,000)        
Canceled and forfeited (in usd per share) $ 1.46        
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Number 548,000 548,000      
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Date Fair Value $ 1.54 $ 1.54      
v3.25.2
Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units - $ / shares
shares in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Restricted Share Units    
Nonvested at beginning of period (in shares) 1.7 2.2
Granted (in shares) 0.7 0.9
Vested (in shares) (0.9) (1.2)
Canceled and forfeited (in shares) (0.1) (0.2)
Nonvested at end of period (in shares) 1.4 1.7
Weighted-Average Grant Date Fair Value per Share    
Nonvested at beginning of period (in usd per share) $ 70.98 $ 57.37
Granted (in usd per share) 108.72 91.06
Vested (in usd per share) 72.07 60.47
Canceled and forfeited (in usd per share) 94.67 74.40
Nonvested at end of period (in usd per share) $ 86.30 $ 70.98
v3.25.2
Share-Based Compensation (Additional Data Related to Restricted Share Unit Activity) (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Restricted Share Units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax $ 64 $ 71 $ 73
Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years) 2 years 2 years 2 years
Total fair value of shares vested during the year $ 60 $ 63 $ 58
Award vesting period (in years) 3 years    
Performance Share Units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total compensation cost, net of estimated forfeitures, related to nonvested restricted share and share unit awards not yet recognized, pre-tax $ 47 $ 46 $ 38
Weighted-average period in years over which restricted share and share unit cost is expected to be recognized (in years) 2 years 2 years 2 years
Total fair value of shares vested during the year $ 49 $ 20 $ 23
v3.25.2
Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units - $ / shares
shares in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Performance Share Units    
Nonvested at beginning of period (in shares) 1.3 1.2
Granted (in shares) 0.5 0.5
Vested (in shares) (0.3) (0.4)
Canceled and forfeited (in shares) 0.0 0.0
Nonvested at end of period (in shares) 1.5 1.3
Weighted-Average Grant Date Fair Value per Share    
Nonvested at beginning of period (in usd per share) $ 97.03 $ 82.17
Granted (in usd per share) 113.88 94.66
Vested (in usd per share) 108.79 62.26
Canceled and forfeited (in usd per share) 0 0
Nonvested at end of period (in usd per share) $ 99.45 $ 97.03
v3.25.2
Share-Based Compensation (Additional Data Related to Performance Share Unit Activity) (Details)
$ in Millions
 12 Months Ended
Jun. 30, 2025
USD ($)
vestingPeriods
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Performance Share Units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized, pre-tax $ 47 $ 46 $ 38
Weighted-average period over which performance share unit cost is expected to be recognized (in years) 2 years 2 years 2 years
Total fair value of shares vested during the year $ 49 $ 20 $ 23
Vesting Period in years for Shares | vestingPeriods 3    
Performance Share Units | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Target performance goal (as a percent) 0.00%    
GIA Common Stock      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized, pre-tax $ 339    
Weighted-average period over which performance share unit cost is expected to be recognized (in years) 2 years    
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested $ 82    
v3.25.2
Schedule II - Valuations and Qualifying Accounts (Details) - USD ($)
$ in Millions
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]        
Allowance for doubtful accounts $ 662 $ 677 $ 720 $ 832
SEC Schedule, 12-09, Valuation Allowances and Reserves, Addition, Recovery 1      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]        
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 2,246 2,317 2,382  
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 1 0 0  
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 2,262 2,360 2,494  
Pricing Disputes [Member]        
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]        
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 38 74    
SEC Schedule, 12-09, Allowance, Credit Loss [Member]        
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]        
Allowance for doubtful accounts 213 233 240 207
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]        
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 88 108 165  
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 1 0 0  
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 109 115 132  
SEC Schedule, 12-09, Allowance, Loss on Finance Receivable [Member]        
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]        
Allowance for doubtful accounts 2 3 6 8
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]        
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 3 2 0  
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 0 0 0  
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction 4 5 2  
Sales Returns and Allowances [Member]        
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]        
Allowance for doubtful accounts 447 441 474 $ 617
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]        
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 2,155 2,207 2,217  
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account 0 0 0  
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction $ 2,149 $ 2,240 2,360  
Disputes        
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]        
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense     $ 109  
v3.25.2
Subsequent Events (Details) - Subsequent Event
$ in Millions
 12 Months Ended
Jun. 30, 2026
USD ($)
Rate
Subsequent Events [Abstract]  
Payments to Acquire Businesses, Gross $ 1,900
Subsequent Event [Line Items]  
Payments to Acquire Businesses, Gross 1,900
Total fair value of shares vested during the year $ 500
Solaris Health [Line Items]  
Subsequent Events [Abstract]  
Business Combination, Voting Equity Interest Acquired, Percentage | Rate 75.00%
Subsequent Event [Line Items]  
Business Combination, Voting Equity Interest Acquired, Percentage | Rate 75.00%